C
60
5214
SD9

The Journal of the American Diabetes Association

diabetes

Volume 17 • 1968

INDEX

By Subject and Author

RECEIVED
APR 14 1969
THE LIBRARY
KANSAS STATE UNIVERSITY



Copyright 1969, by American Diabetes Association, Inc.

DIABETES®

The Journal of the American Diabetes Association

EDITOR, HARVEY C. KNOWLES, JR., M.D., *Cincinnati*

ASSOCIATE EDITORS: DAVID M. KIPNIS, M.D., *St. Louis* • HENRY T. RICKETTS, M.D., *Chicago*

ADVISORY EDITORS: CHARLES H. BEST, M.D., *Toronto* • FRANK N. ALLAN, M.D., *Boston*

ABSTRACTS EDITOR, JOHN A. GALLOWAY, M.D., *Indianapolis* • MANAGING EDITOR, EDWARD W. SANDERSON, *New York*

ART EDITOR, W. I. VAN DER POEL, *New York*

EDITORIAL BOARD

TERM EXPIRING DECEMBER 1968

JAMES ASHMORE, PH.D., *Worcester*
RUBIN BRESSLER, M.D., *Durham*
FREDERICK C. GOETZ, M.D., *Minneapolis*
CHRISTIAN R. KLIMT, M.D., DR. P.H., *Baltimore*
ARNOLD LAZAROW, M.D., PH.D., *Minneapolis*
RACHMIEL LEVINE, M.D., *New York*
ALEXANDER MARBLE, M.D., *Boston*
THEODORE B. VAN ITALLIE, M.D., *New York*

TERM EXPIRING DECEMBER 1969

GEORGE F. CAHILL, JR., M.D., *Boston*
MARVIN CORNBLATH, M.D., *Chicago*
THADDEUS S. DANOWSKI, M.D., *Pittsburgh*
C. F. GASTINEAU, M.D., *Rochester, Minn.*
PAUL E. LACY, M.D., *St. Louis*
VAUN A. NEWILL, M.D., *Cincinnati*
MARVIN D. SIPERSTEIN, M.D., PH.D., *Dallas*
GERALD A. WRENSHALL, PH.D., *Toronto*

TERM EXPIRING DECEMBER 1970

JOHN W. ENSINCK, M.D., *Seattle*
STEFAN S. FAJANS, M.D., *Ann Arbor*
PETER H. FORSHAM, M.D., *San Francisco*
GEROLD M. GRODSKY, PH.D., *San Francisco*
PHILIP M. LECOMPTE, M.D., *Boston*
IRVING H. LEOPOLD, M.D., *New York*
ROGER H. UNGER, M.D., *Dallas*
PETER H. WRIGHT, M.D., *Indianapolis*

ABSTRACTORS

TERM EXPIRING DECEMBER 1968

BURIS R. BOSHELL, M.D., *Birmingham, Ala.*
WAYNE V. GREENBERG, M.D., *Augusta, Ga.*
RONALD K. KALKHOFF, M.D., *Milwaukee*
CHARLES A. ROSENBERG, M.D., *Washington, D.C.*
THOMAS G. SKILLMAN, M.D., *Omaha*
LEON S. SMELO, M.D., *Birmingham, Ala.*

TERM EXPIRING DECEMBER 1969

MARIOS C. BALODIMOS, M.D., *Boston*
SAMUEL B. BEASER, M.D., *Boston*
ARTHUR R. COLWELL, JR., M.D., *Wilmette, Ill.*
HIROMICHI T. NARAHARA, M.D., *St. Louis*
OTAKAR V. SIREK, M.D., PH.D., *Toronto*
ELEANOR A. WASKOW, M.D., *Phoenix*

TERM EXPIRING DECEMBER 1970

JOSEPH D. BROWN, M.D., *Iowa City*
RICHARD A. CHERRY, M.D., *Hayward, Calif.*
PAUL S. ENTMACHER, M.D., *New York*
BERT F. KELTZ, M.D., *Oklahoma City*
CHARLES R. SHUMAN, M.D., *Philadelphia*

DIABETES is published by the American Diabetes Association, Inc., to provide an official Journal for the Association and to furnish the medical profession with information concerning diabetes and related fields of medicine.

Contributions are invited from practicing physicians, clinical and laboratory investigators, and others who have data of importance to offer in these fields. Manuscripts, if suitable, will be accepted providing that the text has not been printed elsewhere.

Matter appearing in DIABETES is copyrighted. Permission to reproduce all or part of papers appearing in it may be granted on application, under appropriate conditions and if proper credit is given. Such permission should be requested by written application to the Secretary of the Association.

All signed articles and editorials are the responsibility of the author(s) and not that of the American Diabetes Association.

The Editors will be pleased to consider for publication papers presented at the Annual Meeting of the American Diabetes Association.

Manuscript Specifications: The length of manuscripts (not including special articles or lectures) should be limited to 5,000 words, exclusive of illustrations, etc. Exceptions to this limitation may be made at the discretion of the Editors.

Communications for the "Brief Notes and Comments" department should not exceed 1,000 words except in unusual circumstances. Figures and tables in these brief communications should be limited to one of each, and references should not exceed twenty in number.

Manuscripts should be typewritten, with double spacing and, if possible, submitted in triplicate together with three copies of figures and photomicrographs.

References should be presented in the style illustrated by the following examples:

For Periodicals—Banting, F. G., and Best, C. H.: The internal secretion of the pancreas. J. Lab. Clin. Med. 7:251-66, Feb. 1922.

For Books—Allen, Frederick M.: Studies Concerning Glycosuria and Diabetes. Cambridge, Harvard University Press, 1913, p. 461.

An abstract or summary of the content of the paper in not more than 250 words should usually appear at the beginning. If possible, this should be self-contained and understandable without reference to the text.

Photographs, drawings, and figures should be suitable for reproduction purposes. Photographs should be unmounted, untrimmed glossy prints. The names of authors should appear on the back. The tops of photographs and figures should be indicated.

Galley proofs are sent to the principal author of each paper, with a price list and order blank for reprints.

All manuscripts and editorial correspondence should be addressed to the Editorial Office, DIABETES, American Diabetes Association, Inc., 18 East 48th Street, New York, New York 10017.

Subscription and Advertising Information

DIABETES: *The Journal of the American Diabetes Association* is published every month by the Association at 18 East 48th Street, New York, New York 10017. Entire contents copyright 1969 by the American Diabetes Association, Inc.; all rights reserved.

Members receive the Journal as part of their membership privileges. The annual subscription rates for nonmembers are as follows: United States, U. S. Possessions, Canada and the Pan-American Union, $14.00 per year; elsewhere, $16.00 per year. Individual copies available at $1.50 each.

Medical students and physicians within five years after completion of medical school and bioscientists who are predoctoral or not more than two years postdoctoral: $7.00 per year.

Correspondence concerning subscriptions should be addressed to the Subscription Department, DIABETES. Checks, money orders and drafts for subscriptions should be made payable to the American Diabetes Association, Inc., and sent to the aforementioned address.

All inquiries about advertising and other business matters should be addressed to the Executive Director of the American Diabetes Association. The publishers reserve in their full discretion the right to accept or reject any proposed advertising and the right to cancel my advertising contract.

SUBJECT INDEX 1968

This index covers all reading matter in Volume 17 of DIABETES. Entries marked with an asterisk (*) indicate material that appeared in the Abstracts only. The Author Index appears on page 26.

A

ABDOMEN
pain in, serum and amylase, 85-86

ACENOCOUMARIN
and insulin and glucagon, *779

ACETATE-1-C-14
incorporation, *116

ACETEST, 281-285

ACETOACETATE
detection of, 398-401
and glucose oxidation, 90-94

ACETOHEXAMIDE
and carbohydrate metabolism, *170
hypoglycemic and uricosuric properties of, *593
and tolbutamide comparison study, *469

ACETONE
detection of, 398-401
and urine testing, 281-285

ACETYLCHOLINE
and insulin secretion, *308-309

ACIDOSIS, DIABETIC, *777-778
and acute cerebral edema, *299-300
and brain function, *714
and insulin sensitivity, 147-150

ACIDOSIS, METABOLIC
and renal gluconeogenesis, *778

ACIDS
Amino. *See* Amino acids.
arachidonic
and alloxan diabetes, *711
p-chloromercuribenzene sulfonic
insulin-like properties, *303-304
ethacrynic
and hyperglycemia, *528
fumaric, 188
glutamic, 188
hydroxyproline, hexosamine and sialic
and diabetic retinal vascular systems, *232
methylpyrazole-3-carboxylic, *231
and free fatty acids, *292
nicotinic
and cyclic 3',5'-adenosine monophosphate metabolism, *711
and free fatty acids, 614
and insulin deficiency in rat, 353-360
and splanchnic metabolism of free fatty acids, *230
nucleic
and insulin, *172
oleic
and gluconeogenesis, 194-205
C-14-orotic, *779
pantothenic
urinary, *292
tricarboxylic
and biguanides, 497
uric
and glycogen storage disease, *470

ACROMEGALY
and carbohydrate tolerance, *175
and diabetes, *407, *470
diagnosis of, *406
and glucose intolerance, *293
and growth hormone, *113
and insulin metabolism, *525
and serum insulin, *775

ACTH. *See* Adrenocorticotrophic hormone

ACTINOMYCIN D
and hexokinase, *300-301
and insulin-produced enzyme activity, *409
and liver metabolism, *711

ADDISON'S DISEASE
and diabetes, *58, *172

ADENINE NUCLEOTIDES
and albumin, 379-380

ADENOSINE 3',5'-CYCLIC MONOPHOSPHATE
assay, *528
and free fatty acid release and ketogenesis, *329
and glucagon, *292, *775
and glucose, nonesterified fatty acid, and cortisol responses, *470
and insulin secretion, *308, *775-776
and lipolysis, *304-305

ADENOSINE TRIPHOSPHATE
and glucagon, *292
isoenzymes, *113

ADENYLCYCLASE
and insulin secretion, *234

ADRENAL GLANDS
deficiency
and diabetes, *172, *588
hyperplasia
and Cushing's disease, *653
and phenylethanolamine-N-methyl transferase
and insulin and glucagon, *470
pregnenolone and progesterone
and stress, *469
and stress, *115, *469

ADRENALECTOMY
and C-14-glycogen deposition, 373-374
and glycogen synthesis, *408
and hyperglycemia, 67-71
and hypoglycemic effect of adipose tissue extracts, 489-491
and insulin secretion, 84
and aminophylline, *292
and pheochromocytoma, *318-319
and plasma glucose
and streptozotocin and nicotinamide, 760-764
and serum insulin-like activity, *714-715

ADRENALIN
and adipose tissue lipolysis, *341
and hyperglycemic response, *111
and insulin release, *655
and tolbutamide, *350

ADRENERGIC BLOCKING AGENTS *234
and diazoxide study, *349
and hypoglycemia, 141-145
and insulin release, *55, *298-299, 617, *775-776
and plasma insulin and blood glucose, *54
and tranylcypromine response, 621-622

ADRENOCORTICOTROPHIC HORMONE
and cholesterol, *469

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

deficiency
and diabetes, *588
and hypoglycemia, *410
diabetogenic action of, *290
and free fatty acid release, *232
and insulin secretion, *173, *775-776
and islet cell adenoma, *717
and ketosis, *300
-mediated insulin secretion and aminophylline, *292

AGE
and antithyroglobulin antibodies, 136-139
and chromium deficiency, *411
and coronary heart disease, *343
and diabetes, *527, *652
of diabetes onset in twins, 697-698
and diabetes prevalence, 277
and diabetic retinopathy, 121-123, 458-459, 463
and fasting serum insulin level, *232
and glucose loading study, 560
and glucose tolerance, *409, *654
and hyperglycemia
and diabetes diagnosis, *348
and insulin resistance, *291
and myocardial infarction, *338
and occult diabetes detection, *525
and pancreas islet cell changes, *291
and prednisone-glucose tolerance and serum lipids, *714
of red blood cells
and fatty acid biosynthesis, *305
and retinopathy, *588
and vitiligo, *712

ALBUMIN
and glucagon, 181
and glucose oxidation, 92
and induced hyperglycemia, 67-71
and insulin adsorption by laboratory glassware, 768-770
and insulin antagonism, 1-7

ALBUMINURIA
and diabetes survey, 225-226
and juvenile diabetes, *591

ALCOHOL
and antabuse reaction, 679-682

ALDEHYDE DEHYDROGENASE
and chlorpropamide, 680
and tolbutamide, 680

ALDOSE REDUCTASE, 240-241, *300

ALLERGY
to insulin
and lymphocyte transformation test, *341

ALLOXAN DIABETES
and arachidonic acid, *711
and cardiac triglycerides, *51
and glucose transport and metabolism, insulin sensitivity, and adipose tissue lipolysis, *411
and hepatic lipid metabolism, *176
and hexokinase, *526-527
and hexosamine, 105-107
and hyperglycemia
and neuromuscular changes, *590
and intestinal 3-O-methyl-D-glucose transport, *524
and islet cell mitotic activity, *306
and liver metabolism, 244-250
and serum insulin-like activity, *714-715
and streptozotocin-induced diabetes, *592
and urinary pantothenic acid, *292

AMBENONIUM CHLORIDE
and gastric neuropathy, *412

AMENORRHEA
and anorexia nervosa, 683
and diabetes, *172

AMERICAN DIABETES ASSOCIATION
annual banquet, 529, 785-786
annual dues increase, 787
annual meetings
of Central Council, 531, 780-785
Twenty-eighth, 59-60, 117-118, 177, 235, 295, 472, 529, 780
Twenty-ninth, 413, 472, 534, 657, 722, 786-787
awards
Banting Medals, 529
Banting Memorial Award, The, 529-530
Lilly, 473, 530, 535-536, 596-597, 659, 723
Research and Development Awards, 595-596, 658-659
Conference on Nutrition and Metabolism, 598
Diabetes Week, 413, 473, 659
film on coma, 118-119, 788
films, 295

FORECAST
"Heart Disease and Diabetes," 119
"Diabetic Neuropathy," 236
"Prediabetes: A New Frontier in Research," 660
"The Tiny but Potent Unit of Insulin," 295
International Congress of Hygiene and Preventive Medicine, 598
International Diabetes Federation Sixth Congress, 595
International Diabetes Federation Seventh Congress, 473, 594
International Diabetes Symposium, 724
Journal
index, 119
necrology, 60, 120, 178, 296, 536, 598, 660, 724, 788
new members, 60, 119, 237, 296, 596, 660, 723
News of Affiliate Associations, 119-120, 177-178, 296, 536, 597, 660, 778
News Notes, 60, 120, 178, 237, 296, 413, 473, 536, 597-598, 660, 723-724, 788
obituaries
Hamwi, George John, 48-49
Root, Howard F., 708
paramedical personnel
first meeting, 659
personals, 60, 120, 178, 237, 296, 473, 598, 788
postgraduate courses, 178, 235-236, 413, 472-473, 534, 594, 598, 657, 719-724, 787
post office fire, 60
publications
diet, 119
Research and Essay Contests, 118, 534-535
research grants programs, 60, 118, 595, 658, 722, 787
research support program, 534
research symposium
seventh, 236, 295, 413, 472, 532-534, 657
reviewers of manuscripts and books, 110-111

AMINO ACIDS
analysis of proinsulin, 726, 731, 733
and high sugar diet, *410
and insulin release, *171, *524-525
release, 436
uptake by perfused liver, *320

AMINOPHYLLINE
and ACTH-mediated insulin secretion, *292

AMNIOTIC FLUID
and diabetic pregnancy management, *320

AMPHOTERICIN B-15, 387

AMPUTATION
and fate of second leg, 520-521

AMYLASE, 437

ANDROGENS
and growth hormone secretion, *716

ANEMIA
and diabetes, *175
macrocytic
and gastrectomy, 132, 146

ANGIOGRAPHY
and diagnosis of pancreatic disease, *772-773

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

ANGIOPATHY
of iris, *590
retinal, *656
and serum glycoproteins, *290-291

ANKLE JERK
and diabetes, 272, 273

ANOREXIA NERVOSA, 683

ANOXIA, 109

ANTAGONISTS. *See* Antibodies to insulin; Synalbumin antagonist

ANTIBIOTICS
and diabetic diarrhea, 385-387

ANTIBODIES
antithyroglobulin
in diabetes, 136-139
to insulin
and coypu insulin, 8-11
and insulin-resistant diabetes, *776-777
and juvenile diabetes, 29
insulin-binding
and insulin requirements, *714
insulin-precipitating, *592
intrinsic factor
and diabetes, *175-176

ANTICOAGULANTS
prothrombin response to
and glucagon and insulin, *779

ANTIDIPHTHEROID SERUM, *331

L-ARABINOSE
and magnesium deficiency, 675-676

ARGININE
and growth-hormone response, *114-115, *174, *772
and insulin release, *171
and insulinopenia measurement, *344
and plasma insulin and glucose response, 28
and pregnancy, *347
response
and pheochromocytoma, *318-319
and serum insulin and growth hormone, *50

ARGYLL ROBERTSON PUPILS
in diabetes survey, 224-225

ARTERIOSCLEROSIS
and blood pressure, 66
and cholesterol
and bile salt synthesis, 75
and diabetic amputees, 520-521

ARYL SULFONYLUREA
and glycogen phosphorylase, *316

ATHEROSCLEROSIS
and carbohydrate and lipids, 12
and carbohydrate tolerance, *649
and diet, 243, 260
in primates, 368, 397
and sulfonylurea therapy, 504-507

ATROMID
and diabetic retinopathy, 458-467

ATROPHY
of testes and seminal vesicles
and arachidonic acid, *711

AUTOANALYZER, *321
and Dextrostix, 405

AZOTEMIA
and anorexia nervosa, 683
and carbohydrate metabolism, *170
and liver glycogen metabolism, *337-338

B

BACILLUS SUBTILIS PROTEASE
and adipose cells, *234

BASEMENT MEMBRANE
capillary
and microangiopathy, 392
glomerular
carbohydrate of, *311

BELL'S PALSY
in diabetes survey, 224-225

BIGUANIDES
and intestinal absorption of glucose, 492-498
and metabolism, 96-102

BILE
insulin in, *55

BILE SALTS
and cholesterol synthesis, 75

BIOTIN
deficiency, *772

BISHYDROXYCOUMARIN
and tolbutamide metabolism, *175

BLADDER
and glucose uptake, *56
and renal disease, *321

BLOOD
capillary
during glucose tolerance tests, *321
cholesterol
and ileal bypass surgery, 208
cholesterol and triglycerides
in maturity-onset diabetes, *326
erythrocytes
in glucose transfer study, *773
estimations
and diabetes detection, *339-340
flow
in limbs of diabetics, *710
and microangiopathy, 390-391
and vagus nerve stimulation, *308-309
glucagon
and insulin release, 192
glucose and ketones
and cortisol, *711
insulin disappearance, 161-163
lactic acid, 142-143
leukocytes
and juvenile diabetes, *335
pyruvate kinase, *331
lipids
and blood pressure, 66
and dietary carbohydrates, 104
and insulin shock treatment, *172
PCO_2
and acidosis, *777-778
pancreatic flow
and insulin secretion, *333-334
pH
and nicotinic acid, 358
red cells
and diabetes, *653
and fatty acid biosynthesis, *305
and glycogen, *718
samples
in free fatty acid turnover study, *317
and insulin, *777
in plasma insulin study, 547-548
sludging
and clofibrate, *651
thrombus formation
and diet, *772
urea
and neuropathy, 270

BLOOD GLUCOSE. *See also* Blood sugar
and adipose tissue extracts study, 489-491
and age, *232
and arginine
and insulinopenia measurement, *344
and coffee, *324
control in diabetics, 570-577
and diazoxide, 257
diurnal
and starvation, *408
and exercise, 214
free fatty acids, insulin and ketone bodies
and sodium B-hydroxybutyrate, *588
and glucagon, *232, *312
and glucose tolerance, *409, *773-774
and growth hormone, *293
and growth hormone response to arginine, *772
and insulin
inhibition, 747
release, *111
and testosterone, *114
in mice, *526
monitoring, 402-405

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

in newborns, *526
and nicotinic acid, 355, 356, 357, 359-360
and obesity, *339
and plasma growth hormone, *527
and prediabetes, *350
regulation, *712
and D-ribose, *774
tests
and diabetes survey, *327-328
and tranylcypromine, 618-619

BLOOD PRESSURE
and adrenalin and tolbutamide study, *350
and coronary arteriosclerosis, 66
and diabetes, *774

BLOOD SUGAR. *See also* Blood glucose
and adrenalin, *350
of AIS-injected rats, 252
during labor, *176
and glycodiazine, 509-511
and growth hormone, *233, *333
and hepatitis, *56
and intestinal hormones, *653-654
and PCO_2 response, *777-778
and phenformin, 481
and pyrazole derivative, *292
and senile diabetes, *170
and sodium β-hydroxybutyrate, *229
tests
and diabetes detection, *525
and twins, *173

BLOOD VESSELS
capillaries
fragility study, *712
and glucose tolerance tests, *321
and hyperglyceridemia, *650-651
microangiopathy, *592
ultrastructure study in South African diabetics, *303

BODY
arms
and glucose uptake, *412
fat
and gastrointestinal hormones, *330
fat cells
and glucose metabolism, *655
and p-chloromercuribenzene sulfonic acid, *303-304
and protein synthesis, *316
feet
and diabetic neuropathy, *113
paresthesias in, 385
forearm
and C-14 glucose flux, *651
hands and feet
and infrared thermography study, *230
height
and Turner's syndrome, *589
limbs
and blood flow, *710
shoulder
"frozen," 228
upper extremities
and diabetic neuropathy, *773
weight. *See* Weight

BOOK REVIEWS
Advances in Carbohydrate Chemistry, Vol. 21, edited by M. L. Wolfrom, 49
Clinical Diabetes Mellitus, by John Malins, 709-710
Color Atlas of Diabetic Retinopathy, by A. Dolenek and A. Takac, 523
Diabetic Care in Pictures, by Helen Rosenthal and Joseph Rosenthal, 709
Essays on History of Nutrition and Dietetics, edited by Adelia M. Beeuwkes, E. Niege Todhunter, and Emma Seifrit Weigly, 523
Fruit and Vegetables, by R. B. Duckworth, 49
Insulin, Membranes and Metabolism, by Peter Rieser, 648
Lydia J. Roberts Award Essays. A Compilation of Essays by the American Dietetic Association, 648
A Modern Pilgrim's Progress with Further Revelations for Diabetics, by Garfield G. Duncan and Theodore G. Duncan, 523
Textbook of Endocrinology, edited by Robert H. Williams, 710

BRAIN
and blood glucose regulation, *712
cerebral cortex
and glycogen synthesis, *471
damage
and tolbutamide hypoglycemia, 522
edema
and diabetic acidosis treatment, *299-300
function
and diabetic acidosis, *714
and Wilson's disease, 269, 285

BUFORMIN
and metabolism, 96-102

BUTYRATE
and plasma insulin, *653

C

CAFFEINE
and blood glucose, *50
and hepatic glucose output, *350
and insulin secretion, *775-776
and lipolysis, *304

CALCIUM
absorption or transport
and vitamin D, 218
and insulin secretion, *468-469

CALORIES
and glucose tolerance and plasma insulin level, *232

CARBACHOL
and insulin secretion, *308-309

CARBOHYDRATES
and analysis of proinsulin, 726
dietary
and blood lipids, 104
consumption in Czechoslovakia, *56
consumption study, *114
and liver lipids, 12
and serum protein, *234
from fatty acids synthesis, *174
of glomerular basement membrane, *311
-induced hyperlipemia, *649
-induced hypertriglyceridemia, *777
intolerance
and idiopathic hemochromatosis, *411
and insulin secretion, *56-57
and lipemia, *649
loading
and diabetes screening, 274-280
metabolism
and chromium, 678
in newborn infants, *173
and obesity, *656
and uremia, *170
in nonhuman primates' sera, *778
noninsulin requiring, *291
and pancreas oxygen consumption, *53
serum protein-bound, *332
tolerance
and acromegaly, *175
and obesity, *591
and strokes, *649

CARBON DIOXIDE
and conversion of glucose U-C-14, *409

CARBUTAMIDE
and glutamic dehydrogenase, *233

CARCINOMA
in Chinese diabetics, 228
and diabetes survey, 225-226
diagnosis
and pancreas scanning, *717
endometrial
and glucose tolerance, *469
gastric
and hypoglycemia, 286-289
islet cell
glucagon-secreting, *327
of pancreas, *772-773

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

of stomach and colon
and Chinese diabetics, 226
and sulfonylurea therapy, 507

CARDIOVASCULAR DISEASE. *See also* Heart disease
and diabetes, 222, *229
and plasma lipids and glucose, *411

CARDIOVASCULAR SYSTEM
and glucagon, *776

CARNITINE
and gluconeogenesis stimulation, *50

CASE REPORTS
adolescent acromegaly, *525
clinical and chemical diabetes in offspring of diabetic parents, *298
diabetes, hypopituitarism, and growth hormone, *654
diabetes and vocal cord paralysis, *302
diabetic coma and pancreatitis, *774
diabetic diarrhea, 385-386
diabetic neuropathy
and diphenylhydantoin therapy, *322
diabetic retinopathy with pituitary suppressive therapy, *318
electroencephalograms and diabetic acidosis, *714
enzyme-deficiency glycogenosis, *589
femoral and popliteal occlusive vascular disease, *326
gigantism, *655
glucagon-secreting pancreatic islet cell carcinoma, *327
hyperglycemia and hyperosmolarity, *231
hypoglycemia and adrenocorticotropic hormone deficiency, *410
insulin allergy and lymphocyte transformation test, *341
insulin sensitivity, hypopituitarism, and diabetic acidosis, 147-149
insulitis and fulminating diabetes, *593
ischemic pancreatopathy, *712
islet cell tumor in neonate, *652
ketoacidosis, 108-109
liver glycogen accumulation, 14-15
multiple endocrine adenomata
and insulin secretion studies, 83-86, *299
myocardial infarction in young diabetics, *338
neonatal islet cell adenoma, *717
pregnancy in mothers with juvenile-onset diabetes, *334
sulfonylurea-induced hypoglycemia, 522
swallowing disorder in diabetic neuropathy-gastroenteropathy, *334

CATARACTS
in diabetes survey, 224-225
and high sugar diet, *410
and juvenile diabetes, *591

CATECHOLAMINES
and heart action, *775

CELIAC DISEASE
and lactose intolerance, *776

CELLULOSE POWDER
in plasma insulin immunoassay, 444-457

CHICKEN POX
and diabetes onset, *316

CHILDREN
adolescents
and acromegaly, *525
and obesity, *342
and carbohydrate-induced hypertriglyceridemia, *777
and celiac disease
and lactose intolerance, *776
with chemical diabetes
and insulin reserve, *336-337
diabetic
and glucose tolerance in parents, *469-470
and thyroid antibodies, 136
of diabetic parents
and clinical and chemical diabetes, *298
and fasting serum insulin level, *232
and genetic studies of diabetes, *471
glucose tolerance tests
and capillary blood standard values, *321
and growth hormone
and hypothyroidism, *526
response to insulin, *115
and hyperglycemia and hyperosmolarity, *231
and hypoglycemia
and diazoxide, *170, *173
and synalbumin insulin antagonism, 557-559
and insulitis and fulminating diabetes, *593
and ketoacidosis
and glucagon and tolbutamide, 133-135
and L-leucine
and serum insulin, *589
obese
and plasma glucose, free fatty acids, and immunoreactive insulin, 261
and plasma growth hormone, 610, 667, 672
and tolbutamide tolerance tests, *113

CHINESE
and diabetes survey, 219-228

CHLOROPHENOXYISOBUTYRATE
See Clofibrate

CHLOROTHIAZIDE
-diazoxide
toxic effects of, *592

CHLORPROPAMIDE
and diabetes prevention, *588
and elderly diabetics, *652
and metformin compared, *524
and pancreatic homografts, *715
and plasma insulin and glucose response to meals and fasting, *650
and serotonin metabolism, 680-681

CHOLATE
and cholesterol synthesis, 75

CHOLELITHIASIS
in Chinese, 227

CHOLESTEROL
conversion to pregnenolone, *469
esters
and fatty acid content, 89, 95
and hypercholesteremia and atherosclerosis, 243, 260
and pancreatectomy, *345-346
synthesis
bile salts inhibition of, 75

CHOLINOMIMETICS
and insulin secretion, *308-309

CHROMATOGRAPHY
adsorption
and serum insulin-like activity, *716
CM-cellulose
of proinsulin, 730
column
of proinsulin, 726
DEAE-cellulose
and purification of proinsulin, 730
DEAE-Sephadex
and fluoresceinthiocarbamyl insulins, *468
ion-exchange
of aminoethylated insulin A and B chains, *590

CHYLOMICRONEMIA
following pancreatectomy, *345-346

CIRCULATION. *See* Blood flow

CITRATE
and phosphofructokinase, 204

CLINITEST, 281-285

CLOFIBRATE, *651

COMA
and hyperglycemia without ketonemia, *525
hyperglycemic nonketotic
in insulin-dependent diabetes, *525

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

and ketoacidosis, 108-109
and liver glycogen, 13-14
and pancreatitis, *774

CONGENITAL DEFECTS
and insulin antagonism, *58, *116

CORONARY DISEASE. *See* Cardiovascular disease, Heart disease

CORTISOL
antagonism
in insulin bioassay, *714-715
and glucose homeostasis, *711
and liver glycogen synthesis, *408
and renal gluconeogenesis, *348
responses
and adenosine 3',5'-monophosphate, *470

CORTISONE
-glucose tolerance
and oral contraceptives, *590
and growth hormone, *336
and pancreatic homografts, *715

CORTICOTROPHIN
-induced hypoglycemia, *526
synthetic
and free fatty acid release, *232

CREATININE, 398
clearance
and diabetes, *408

CREATINURIA
prevention
and insulin, *654

CUSHING'S DISEASE
and adrenocorticol control, *653

CYCLOHEXIMIDE
and insulin-produced enzyme activity, *409

CYSTEINE
and insulin synthesis, *656

CYTOCHROME OXIDASE
and biguanides, 497

CZECHOSLOVAKIA
carbohydrate consumption survey, *56

D

DECANOYLCARNITINE
and gluconeogenesis, 194-205

DEOXYCHOLATE
and cholesterol synthesis, 75

2-DEOXY-D-GLUCOSE
and gastric motility, *234
and oxygen uptake, *53

2-DEOXYGLUCOSE
and glucagon, *340
and glucose, *234
and insulin and glucose release, 190

DEOXYRIBONUCLEIC ACID, *see* DNA

DEXAMETHASONE
and ketosis, *300
and lipolysis, *50

DEXTROSE
and hypoglycemia, 522

DETROSTIX, *339-340
and blood glucose monitoring, 402-405

DIABETES INSIPIDUS
and ketoacidosis, 108-109

DIABETES MELLITUS
and acromegaly, *175, *470
and ACTH deficiency, *588
and adipose tissue lipolysis, *231
and Addison's disease, *58
and amputation
and fate of second leg, 520
and angiopathy of iris, *590
and antidiphtheroid sera, *331
and antihydroglobulin antibodies, 136-139
and arginine, *115
and atherosclerosis, *649
Banting Memorial Lecture on, 599-608
and bladder dysfunction
and renal disease, *321
and blindness
and touch perception, *302
and blood flow in limbs, *710
and blood glucose control, 570-577
and blood pressure, *774
and blood sugar
and glycodiazine, 509
"borderline," *328
and capillary fragility, *712
and carbohydrate intolerance, *56-57
chemical
and insulin reserve, *336-337
in twins, 693-703
and chromium, 678
and conjunctival microaneurysms, *303
control
and neuropathy, 270-273
and coronary heart disease, *229
and creatine clearance, *408
detection
and chemical diabetes, *716
"DAC" Detection Program for Diabetes, 274-280
and enzyme-strip blood estimations, *339-340
and glucose tolerance variations, *50
and growth hormone, *336
diagnosis, *230
and glucose tolerance tests, *319
and hyperglycemia in elderly, *348
and obesity, *323
and diarrhea, *653
and antibiotics, 383-387
and diet, *323, *332-333
and high fat, *342-343
duration
and gastric mucosa study, *319
and neuropathy, *773
and edema, *331-332
and endometrial carcinoma, *469
etiology, *649-650
and eye intraocular pressure and aqueous outflow, *50
and free fatty acid metabolism, 353-360
and fructose metabolism
and glucagon, *776
fulminating, *593
and functional microangiopathy, 388-394
genetic studies of
and glucose tolerance tests, *471
gestational
and placenta, *406
and glomerulosclerosis, *301
and glucose-fatty acid cycle, 76-81
and glucose levels
and starvation, *408
and glucose tolerance
and hypoglycemic effects of adipose tissue extracts, *314-315
and reserpine, *112
and glycerol, *291
and glycogen synthesis, *408
and gold thioglucose-induced lesions, *408
and growth hormone, *293, 661-666, *772
and hemochromatosis, *468
and hexose transport, *524
and hyperglycemia
and chromium, *777
and hyperglycemic nonketotic coma, *525
and hyperinsulinism
and hepatic cirrhosis, *340
in Pima Indians, *291
and hypoglycemia, 557-559
and monoamineoxidase inhibitors, 628-633
and hypopituitarism
and growth hormone, *654
and hypothyroidism, *409
and impotence, *349-350
and infrared thermography, *230
and insulin
"abnormal," *592
antagonism, 1, *116
deprivation and triglyceride removal, 127-131
precipitating antibodies, *592
release, *297, 685-691

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

requirements and insulin-binding antibodies, *714
resistance and insulin antibodies, *776-777
response, *290, *527-528
response to glucagon, *297
secretion, and amino acids and glucose, *524-525
and intrinsic-factor antibody, *175-176
and ischemic mononeuropathy multiplex, *655-656
juvenile
complications, *591
in diabetes survey, 279-280
and emotional disturbance, *317-318
and family history, *316
and hair chromium content, 517-519
and inflammatory cycle, *774
and insulin deficiency, 27-32
and insulin immunoassays, 133-135
and insulin reserve, *326
and insulin resistance, *291
and leukocyte function, *335
management, *718
and microangiopathy, 388-389
and motor-nerve conduction studies, *114
and obesity and insulin secretion, *320-321
and parental glucose tolerance, *469-470
partial remission of, *406
and plasma-insulin, *114
and renal changes, *171
juvenile-onset
and pregnancy management, *334
and leukocyte pyruvate kinase, *331
and lipid thrombi, *112
and liver disease, *172-173
and liver metabolism, 244-250
and lymphocytic thyroiditis, *230
maternal
and epinephrine release in infants, *292-293
and fetus, 362
and pancreas beta cell morphology of neonates, *306-307
maturity-onset
and blood cholesterol, triglyceride, and body weight variability, *324
and glucose absorption study, 492-498
and insulin radioimmunoassays, 61-65
and vitiligo, *712
and microangiopathy of rectal mucosa capillaries, *592
and myocardial glycogen, *589-590
and myocardial infarction, *338
and neovascular glaucoma, *327
and nervous system changes, *294
and obesity, *55, *112
and chlorpropamide and metformin treatment compared, *524
in old age, *652
and oral contraceptive agents, *307, *307-308
parental
and clinical and chemical diabetes in children, *298
and PCO_2 response, *777-778
and phenformin
and alcohol and hyperlactatemia, *654
and pituitary cyroablation, 634-640
and plasma cortisol response to insulin
and circadian rhythm, 124-126
and plasma insulin, 547-555
in mothers of heavy infants, 37-46
and plasma lipids and glucose, *411
and postoperative shock, *468
and potassium and carbohydrate metabolism, *230
and prediabetes diagnosis, 17
prevalence, *114, *590-591
prognosis
and oral hypoglycemic agents, *407
and proinsulin, 735
and protein synthesis, *58
and red blood cells, *653
remission
and serum insulin levels, *337
and renal glucose threshold, *779
and retinal angiopathy, *232, *656
and retinal mural cells, *170
screening, 274-280, *345
and aged patients, *525
and fibroblasts conversion of glucose-C-14, *326
and glycosuria, *590
senile, *170
and serum fatty acids, *471
and serum fucose assays, *471
and serum glycoproteins, *290-291
and serum protein-bound carbohydrates, *332
severity
and insulin/glucose ratio, *323-324
and sorbitol pathway, *300
in South Africa
capillary ultrastructure study, *303
and streptozotocin and nicotinamide, 762-763
and sulfonylurea therapy, 503-507
surveys
and blood glucose values, *327-328
in Hong Kong, 219-228
among Navajo Indians, *776
in Pennsylvania, *114-115
and prevalence and characteristics, *527
among Seneca Indians, *324
in Trinidad, *716
treatment, *328, *588
and diurnal plasma triglyceride, *470
and sodium cyclamate and sodium saccharin, *346
and tolbutamide and acetohexamide, *469
in twins, 693-703
unstable, *342
and liver glycogen accumulation, 13-16
and urinary pantothenic acid, *292
and urinary steroid excretion, *407
and vascular disease study, *326
and weight gain, serum lipids, and vascular disease, *412

DIARRHEA
and antibiotic therapy, 385-387
in diabetes survey, 224-225
and neuropathology, *653

DIAZOXIDE
and carbohydrate metabolism, 256-259
and chlorothiazide, *592
and glucagon, *340
and glucagon-induced insulin secretion, *772
and hypoglycemia of infancy, *170, *173
and immunoglobulin-G, *170
and islet cell adenoma, *717
and leucine-sensitive hypoglycemia, *406-407
and potassium deficiency, *715

DIET
and atherosclerosis in primates, 368, 397
carbohydrate
and blood lipids, 104
consumption, *114
free, and metabolism, *174
chromium
and carbohydrate metabolism, *407-408
and eye lesions, 512
and glucose tolerance, *411
low, 645
coffee
and glucose tolerance, *324
copper
and Wilson's disease, 269, 285
and diabetes, 124-126, *332-333, 752-759
of diabetics in Hong Kong, 222
and diabetic retinopathy, 458
and epididymal adipose tissue and metabolism in rats, *528
and fatty acids, 89, 95
and heart disease, 12
high carbohydrate
and hypertriglyceridemia, *174
high carbohydrate and high fat
and hydrochlorothiazide, *176

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

high fat
and serum lipids of diabetic dogs, *342-343
high galactose
and enzyme studies, *300
high protein-fat
versus high carbohydrate, *323
high sugar
and urine amino acids, *410
high sugar and high starch
and thrombus formation, *772
and hypercholesteremia and atherosclerosis in monkeys, 243, 260
and hypertriglyceridemia, *111-112
and induced hyperglycemia, 67-69
and insulin inhibition study, 746-747
and insulin standards, 707
leucine-free, *170-171
low carbohydrate, *56
low potassium
and oral hyperglycemic agents, *715
magnesium-deficient
and glucose tolerance, *589
and pancreatic pathology, *718
meal size and frequency
and plasma insulin response, 72-74
and mebanazine study, 628, 629
and paralytic poisoning, 36
and phenformin study, 481
and plasma amino acid, *57
protein
and insulin release, *297
and quick cooking dehydrated pulses and beans, 508

DIHYDROXYACETONE-P
and oleic acid, 196

DIPHENYLHYDANTOIN
and diabetic neuropathy, *322

DISACCHARIDASE
deficiencies, *233

DISACCHARIDES
and evacuation from stomach, *293

DNA
in placentas, *234
and RNA transcription, *329

DOWN'S SYNDROME, *115
and growth hormone level, 672

DUMPING SYNDROME
and gastrectomy, 132, 146

DUODENOGRAPHY
and diagnosis of pancreatic disease, *772-773

DUPUYTREN'S CONTRACTURE, 227-228

DWARFISM
and growth-hormone, *116, 672
and arginine, *115
and carbohydrate metabolism, *525
and hypoglycemia, *171
and spontaneous puberty, *718

E

EDEMA
cerebral
and diabetic acidosis treatment, *299-300
and diabetes, *331-332

ELECTROCARDIOGRAMS
and ketoacidosis, 109

ELECTROENCEPHALOGRAMS
and diabetic acidosis, *714

ELECTROPHORESIS
disc-gel
of proinsulin, 726
and insulin biosynthesis study, *309-310

EMBRYOS
adipose tissue
and glucose-U-C-14 metabolism, *525

ENDOCRINE GLANDS, 603-604
adenomatosis, 86-87
and hypersecretion of insulin, glucagon, and gastrin, *299
and pituitary cyroablation, 637-638

P-ENOLPYRUVATE
and oleic acid, 196

ENZYMES
deficiency, 735
-deficiency glycogenosis, *589
and fatty acid synthesis, *113
and hexokinase and glucokinase, *300-301
and hyperglycemia, 475-479
and insulin
adsorption, 625
deprivation, 611-615
release, *309
and liver glycogen, 14-16
of pancreas islets, *524
and protein value assays, 436
pyruvate kinase
and carbohydrate metabolism, *331
and reduction of cooking time of pulses, 508
of sorbitol pathway, 239-243, *300

EPINEPHRINE
and adrenergic blocking agents, *54, 142-145
and beta cell granulation, *322-333
and fat mobilization
and pyrazole derivative, *292
and glucagon, *340
and gluconeogenesis, 620
and glucose turnover, *717
hyperglycemia
and spinal cord section, *712
and insulin release, *55, 617, *718, 775-776
and liver amino acid uptake, *320
and potassium deficiency, *715
release
and infant hyperglycemia, *292-293

ERYTHROBLASTOSIS FETALIS
and pancreas insulin content, *51

ERYTHROCYTES
and fatty acid biosynthesis, *305
and glucose, *57
glucose transfer in
and N-ethylmaleimide and 1-fluoro-2,4-dinitrobenzene, *651

ESCHERICHIA COLI, *775
and glucose metabolism, *115

ESOPHAGUS
and diabetes, *172
and diabetic neuropathy, *322
and neuropathy-gastroenteropathy, *334

ESTROGEN
and glucose tolerance, *714
and insulin secretion, *590
-progestin therapy
and glucose intolerance, *53

ETHANOL
and disposition of alimentary fat, *306
hypersensitivity, 679-682
and hypoglycemia
and pituitary function, *588
and islet cells
priming effect, *298
and phenformin, *654

N-ETHYLMALEIMIDE
and glucose transfer in erythrocytes, *651

ETHYNODIOL DIACETATE MESTRANOL, *53

ETIOCHOLANOLONE, *407

EXERCISE
and glucose uptake, *412
and insulin secretion, 209-216, *718
test, *229

EYE
blindness
and touch perception and diabetes, *302
conjunctiva
and microaneurysms, *303
diabetic changes, *50, 459-460, 463-464
and diabetic neovascular glaucoma, *327

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

function
and pituitary cyroablation, 638
iris
and diabetes, *590
lesions
and chromium, 512
retina. *See* Retina
vision
and diabetic retinopathy, 121-123
and hypophysectomy, *528

F

FAMILY HISTORY
and carbohydrate-induced hyperlipemia, *649
and cardiovascular disease
and diabetes incidence, *411
and clinical and chemical diabetes, *298
of diabetes
and fetal outcome, *294
and diabetes diagnosis, *230
and diabetes survey in Hong Kong, 221-222
and glucose loading study, 560, 563-564
and hypersecretion of insulin, glucagon, and gastrin, *299
and insulin release, 685-691
and insulin reserve, *336-337
and juvenile diabetes, *316
and microangiopathy, *412
and obese children, 261, 264
and pituitary dwarfism, *718
of twins in diabetes study, 698

FATTY ACIDS
biosynthesis in erythrocytes, *305
dietary
and atherosclerosis, 368, 397
free
and aging, *714
and beta-adrenergic blockade, 142-143
and cirrhosis, *317
and cortisol, *711
and glucagon, theophylline, and cyclic AMP, *329
and glucose utilization, *528
and growth hormone diabetogenic action, *653
and hypoglycemia, *233
and hypoglycemia and hyperinsulinemia, *409
and induced diabetes, *592
and insulin deficiency, 353-360
and juvenile diabetes, 29, 31-32
and ketone bodies, *54
during labor, *176
and nicotinic acid, *230, 614
and norepinephrine, growth hormone, and fasting, *290
and plasma insulin, 76-81
release, and corticotropin and ACTH, *232
and triglyceride fatty acid, *234
turnover in insulin deprivation, *317
in venous and arterial blood, *777
and glucose, 422-426
and growth hormone, *112
nonesterified
and adenosine 3',5'-monophosphate, *470
and pregnancy, *293-294
and pregnancy, *55
short-chain
and plasma insulin, *653
synthesis
and diabetes, 249
and exogenous insulin, 362-367
and proinsulin, *310
transport, *51-52, *52, *52-53
utilization
and exercise, 209
in rats with ventromedial hypothalmic lesions, *301

FETUS
and exogenous insulin, 362-367
and glucosuria, *294
growth and biochemical composition and insulin, *411
mortality, *334
pancreas
and effect of glucose on insulin content, *651
plasma free fatty acids and glucose, *115
plasma insulin, *588
survival
and diabetes, *410
and pregnancy complications, *291

1-FLUORO-2,4-DINITROBENZENE
and glucose transfer in erythrocytes, *651

FRUCTOSE
and amino acid incorporation, *772
and diabetes, *291
and liver urea formation, *411
phosphorylate, *113

FRUCTOSE-6-P
and oleic acid, 196

FUROSEMIDE
and hyperglycemia, *528

G

GALACTOSE
and insulin, 605

GALACTOSEMIA
detection, *53
and sorbitol pathway, *300

GANGRENE, 458
and amputation, 520
in diabetes survey, 223-224

GASTRECTOMY
and children, 132, 146

GASTRIN, *233
hypersecretion, *299
and plasma insulin, *653-654

GASTROINTESTINAL TRACT
cancer
and hypoglycemia, 286-289
and diabetes, *172
and diagnosis of pancreatic disease, *772-773
disease
and Chinese diabetics, 226
gastric mucosa
and ketoacidosis, *319
glucose absorption
and biguanides, 492-498
hormones
and coffee, *324
and insulin absorption, 625-627
and insulin secretion, *592, *653-654
and isolated liver, fat, and pancreas, *330
insulinogenic factors, 179
3-O-methyl-D-glucose transport
and alloxan diabetes, *524
motility
and glucagon, *54
mucosa
glucagon-producing cells, *293
neuropathy, *412
and sugar malabsorption, *233

GENES
and blood glucose level, *328
and glycogen storage disease, *294
for insulin, 735

GIGANTISM
and serum growth hormone and insulin, *654

GLAUCOMA, DIABETIC, *327

GLOMERULI
basement membrane
carbohydrates, *311

GLOMERULOSCLEROSIS
in genetically diabetic mice, *301

GLUCAGON
assays, *116
and blood sugar, *233
and cardiovascular system, *776
double antibody immunoassay, 179-185
and free fatty acid release, *329
and fructose metabolism, *776

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

and glucokinase, 612-613
and glucose clearance rate, *326
and glucose turnover, *717
and glucose U-C-14 metabolism, *525
and heart action, *775
hypersecretion, *299
immunoassay, 187-188
-induced insulin secretion
and diazoxide, *772
and insulin, 749-750
and insulin release, *53, *207, *308, *311-312, *592, *651, 685-691
and aminophylline, *292
and intestinal motility, *54
-like immunoreactivity, *321-322
and lipids and glucose, *232
and 5-nucleotidase in islets, *292
and phenylethanolamine-N-methyl transferase, *470
and plasma insulin, 133-135, *653-654
portal venous immunoreactive
and insulin, 2-deoxyglucose, epinephrine, and diazoxide, *340
and potassium deficiency, *715
-producing cells
in intestinal mucosa, *293
and prothrombin response to anticoagulants, *779
release
and glucose concentration, 187
and renal hemodynamics, *173
response
in premature infants, *306
secretion
and glucose, *312
and obesity, 267
and pancreas α-cell study, 152-159
-secreting pancreatic islet cell carcinoma, *327
and uremia, *170

GLUCAGON I-125
in glucagon immunoassay, *116, 179-180, 182

GLUCOCORTICOIDS
and corticotrophin-induced hypoglycemia, *526
and growth hormone response to insulin, *115
production
and insulin and glucagon, *470

GLUCOKINASE
and insulin release, *406

6-P-GLUCONATE
assay
and hyperglycemia, 476-478

6-P GLUCONATE DEHYDROGENASE, *309

GLUCONEOGENESIS
and biguanides, 96
and carnitine, *50
and decanoylcarnitine, 194-205
and hydrazine, *231
and infection, *775
and insulin and fatty acids, *231
and metabolism, 96-102
and pyruvate oxidation, 96
and tranylcypromine, 619-620

GLUCOSAMINE, 760

GLUCOSE
absorption
and biguanides, 492-498
from colon and rectum, *55
administration methods
and insulin response, *338-339
assimilation
and coefficient K, of Conard, *588
and beta cell granulation, *322-333
disappearance rates
and insulin B chain-albumin complex, 4-7
and insulin release, 690
and fatty acids, 422-426
and growth hormone, *653
and free fatty acid release, *54
homeostasis
and cortisol, *711
incorporation
into liver glycogen, 247
infusions
and plasma glucose and insulin response, *524
and insulin
and glucagon release, 187-192
in rat fetal pancreas cultures, *651
-insulin ration, *323-324
insulin response to
in normals and diabetics, *527-528
and obesity, *712
and prediabetes, *350
and insulin secretion, *53
and amino acids, *524-525
and aminophylline, *292
intolerance
and ethynodiol diacetate-mestranol, *53
in hypernatremic rats, 579-581
among Navajo Indians, *776
and obesity, *315
and young coronary heart disease patients, *343
levels
in perfused rat pancreas-duodenum preparation, *338
and liver gluconeogenesis, *717
and liver urea formation, *411
loading
and insulin release, 685-691
insulin response to, *525, 560-569
and liver glycogen synthesis, *408
and plasma glucose response, *319
and plasma insulin and growth hormone, *714
loading tests
and biguanide, 492-498
metabolism
and biguanides, 96-102
and cations, *304
and *E. coli*, *115
and phenformin, 481-488
and milk production, *114
output by kidney
and starvation, *305
oxidase, 423
oxidation
and acetoacetate, and palmitate, 90-94
and insulin, 741
and proinsulin, *310
and oxygen uptake, *53
and pancreas beta cells, *589
and pancreatic glucagon secretion, *312
passage across vascular beds, *339
phosphorylation
and mannoheptulose, *527
and plasma amino acid, *574
and pregnancy, *55
production
and fatty acids, 194-205
regulation
and caffeine, *350
responses
and adenosine 3',5'-monophosphate, *470
and chlorpropamide, *650
to growth hormone, *528
and pheochromocytoma, *318-319
and RNA synthesis, *309
serum insulin response to
and acromegaly, *775
and serum triglycerides, *528
tolerance
and blood glucose, plasma insulin, and growth hormone levels, *409, *773-774
and caloric intake, *232
and chromium, *411, 512, 517-519, 678
circadian variation of, *314
and cirrhosis, *317
and coffee, *324
diurnal variation, 50
and endometrial carcinoma, *469
and heredity, 693-703
and hypothalamus, *112
and insulin insensitivity, *715-716
and insulin response to glucagon, *297
and liver disease, *327
and magnesium deficiency, *589
and monoamineoxidase inhibitors, 629
and oral contraceptives, *344-345, *590, *592
and ovarian changes, *714

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

and pancreas islet changes, *291
in parents of diabetic children, *469-470
and potassium, *57
and pregnancy, *291
in rats, *654
and serum insulin response to glucose, 17-25
and Staub-Traugott effect, *346-347
and tolbutamide, 748
treatment of abnormalities in, *328
tolerance tests
and acromegaly, *406
and children of diabetic parents, *298
and diet, *56
and genetic studies of diabetes, *471
and glucose uptake and production during, 415-420
and growth hormone and insulin secretion study, 663
in infants and children, *321
and insulin inhibition study, 746-747
in insulin secretion study, 210-211
and mothers of heavy infants, 37-46
in newborn infants, *412
in obese hyperglycemic mice, *593
and obesity, 261-268
oral and intravenous compared, *468
and plasma glucose and insulin, 560-569
in pregnancy, *112, 362
and racial differences, *328-329
among Seneca Indians, *324
and serum fucose levels, *471
and tolbutamide therapy, *344
and urine insulin output, *408
transport
and insulin, *57
transport and metabolism
and alloxan diabetes, *411
turnover
and epinephrine and glucagon, *717
and phenformin, 481-482
and D-ribose, *713
uptake
and diabetes, 248
and exercise, *412
in forearm muscle, *650
and growth hormone, *171
and insulin and NSILA, *116
in perfused heart, 432-434
of rat adipose tissue, *528
uptake and production
and oral glucose tolerance tests, 415-420
urinary excretion
and pregnancy, *56
utilization
in biotin-deficient rats, *772
of p-chloromercuribenzene sulfonic acid-treated fat cells, *303-304
and exercise, 209-216
and hemochromatosis, *412
and hypothalamic lesions, *301
and plasma glycerol, triglyceride, and free fatty acids, 76-81
in pregnancy, *293-294
utilization and production
in diabetic rats, 253
and insulin, 246
in venous and arterial blood, *777
and D-xylose penetration, *229

GLUCOSE-C-14
conversion by fibroblasts and insulin, *326
forearm distribution, *651
utilization
and exogenous insulin, 362-367

GLUCOSE-I-C-14, 420
metabolism
and insulin, *334-335

GLUCOSE-6-PHOSPHATASE
in cerebral cortical slices, *471
and insulin deprivation, 611

GLUCOSE-6-PHOSPHATE
dehydrogenase, *175, *309
and hyperglycemia, 475-479

GLUCOSE U-C-14
conversion to carbon dioxide and glyceride glycerol, *409

α-GLUCOSIDASE, *589

GLUCOSURIA
in pregnancy, *294

GLUTAMATE
dehydrogenase
and carbutamide, *233

GLYCERALDEHYDE-3-P
and oleic acid, 197

2-P-GLYCERATE
and oleic acid, 196

3-P-GLYCERATE
and oleic acid, 196

2-P-GLYCERATE FRUCTOSE
and oleic acid, 196

GLYCERIDE
transport, *51-52, *53

GLYCERIDE-GLYCEROL
and glucose U-C-14 conversion, *409
synthesis
and glucagon, *525

GLYCEROL
and beta-adrenergic blockade, 142-143
and diabetes, *291
and insulin response, 76-81

GLYCEROPHOSPHATE DEHYDROGENASE
in pancreatic islet tissue, *524

GLYCODIAZINE
and blood sugar, 509-511

GLYCOGEN
and rat fetus studies, 363
and red blood cells, *718
synthesis
and "abnormal" insulin, *592
and glucose, cortisol, and insulin, *408
and insulin, *471
and stress, *115

GLYCOGEN-C-14
deposition
and adrenalectomized or hypophysectomized rats, 372-373

GLYCOGEN PHOSPHORYLASE
and aryl sulfonylurea hypoglycemia, *316

GLYCOGEN STORAGE DISEASE
and blood cell studies, *718
Type I
and uric acid production, *470
Type III, *294
Type IV, *589

GLYCOGENOLYSIS
and diabetes, 245

GLYCOGENOSIS
and branching enzyme deficiency, 589*

GLYCOLYSIS
and insulin release, 192
and plasma albumin, 374-383
and potassium transport, *301-302

β-GLYCOSIDASES
in pancreas islets, *409

GLYCOSURIA, 385, 386
and diabetes screening, *590
and urine tests, 284

GOITER
in Chinese diabetics, 228

GOLD THIOGLUCOSE
-induced lesions
and insulin deficiency, *408

GOUT
in Chinese diabetics, 228

GROWTH
and hypothyroidism, *526
and obese-hyperglycemic syndrome, *593

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

and plasma growth hormone response to insulin-induced hypoglycemia, *115

GROWTH HORMONE
and acromegaly, *470, *525
assays
in juvenile diabetics, *406
and pheochromocytoma, *318-319
and blood glucose regulation, *293
and carbohydrate metabolism
and hypopituitary dwarfs, *525
and cardiac glycogen determination, *589-590
and cortisone, *336
deficiency
and dwarfism and spontaneous puberty, *718
and hypothalamic lesions in rats, *301
diabetogenic action of, *290, *653
and free fatty acids and glucose metabolism, *290
and glucose tolerance, *409, *773-774
and glucose uptake, *171
and hypopituitarism
and diabetes, *654
and hypothalamic lesions, *651-652
and insulin
action, *353
disappearance, *112
resistance, *315
secretion, 661-666
levels
and liver disease, *327
and Staub-Traugott effect, *346-347
and lipolysis, *50
and mammosomatotropic tumor, *308
microradioimmunoassay, *337
and pregnancy, *55
release
and arginine infusion during pregnancy, *347
and insulin and arginine, *173-174
and insulin and pyromen, *716-717
by ox anterior-pituitary slices, *174
response
and myxedema, *407
and nutrition, *528
response to glucose
and acromegaly, *406
response to hypoglycemia
in pregnancy, *527
secretion
and androgens, *716
and arginine, *772
and hypophysectomy, hypophyseal stalk section, and proton beam irradiation, *318
and insulin and 2-deoxy-D-glucose, *176
and insulin-induced hypoglycemia, *116
and protein, *175
and serum binding, *55
and Turner's syndrome, *589

H

HEART
catheterization
and insulin assays, *777
glycogen determination, *589-590
perfused
and insulin study, 427-435
rate
and glucagon, *775

HEART DISEASE
and carbohydrates and lipids, 12
coronary
and hyperinsulinism and hypertriglyceridemia in young patients, *343
and glucagon, *776
ischemic
and carbohydrate-induced hypertriglyceridemia, *777

HEMOCHROMATOSIS
and diabetes, *468
and diabetic syndrome, *411-412

H. PERTUSSIS VACCINE
and anti-insulin serum production, 513-516

HEMORRHAGE
cerebral
and sulfonylurea therapy, 504-505
of gastric mucosa, *319
gastrointestinal
and sulfonylurea therapy, 507
and hepatitis, *56
retinal, *656

HEPARIN
and insulin response, 80-81
and plasma free fatty acids, 424-425, 427

HEPATOMEGALY
and Chinese diabetics, 226
and liver glycogen, 13-16

HEREDITY
and diabetes, 693-703
and blood glucose survey, *327-328
and glomerulosclerosis, *301
and glucose tolerance test studies, *471
and vascular disease, *412
and hyperlipemia, *649
and islet-cell adenoma, *299
and leucine sensitivity, 170-171
and pituitary dwarfism with spontaneous puberty, *718

HEXOKINASE
and alloxan diabetes, *526-527
hormonal control of, *300-301
and insulin deprivation, 611
and insulin release, *406
isoenzymes, *409

HEXOSAMINE
and alloxan diabetic vitreous humor and insulin, 105-107

HEXOSE
monophosphate shunt
and *E. coli*, *115
and hyperglycemia, *309, 475-479
transport
and diabetes, *524

HOMOGRAFTS
neonatal pancreatic
endocrine function, *332
pancreatic
in golden hamsters, *715

HONG KONG
diabetes survey, 219-228

HORMONES
and coffee, *324
of endocrine pancreas
and insulin release, *330
gastrointestinal
and liver, fat, and pancreas, *330
and glucose tolerance, *53
and hexokinase control, *300-301
and insulin secretion, *775-776, *779
intestinal
and insulin secretion, *592
and plasma-insulin, *233, *653-654
and ketosis control
in hypophysectomized, pancreatectomized rat, *300
and lipid mobilization, 150
mobilization
and coffee, *324
neurohypophyseal
and insulin secretion, *172
parathyroid
and vitamin D, 218
and renal gluconeogenesis, *348
and unstable diabetes, *342

HYDROCHLOROTHIAZIDE
and high fat or high carbohydrate diet, *176

HYDROCORTISONE
and potassium deficiency, *715

β-HYDROXYBUTYRATE
and Ketostix, 400

HYDROXYHEXAMIDE
hypoglycemic and uricosuric properties, *593

5-HYDROXYTRYPTOPHOL, 682

HYPERCALCEMIA, *299

HYPERCHOLESTEREMIA
and diet, 243, 260
and ileal bypass, 208
and phenformin hydrochloride, *711

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

HYPERGLYCEMIA
and adrenalin, *111-112
and adrenergic blocking agents, *54
and alpha-cell ultrastructure, 152-159
asymptomatic, *328
and blood glucose monitoring, 402-405
and chromium, *777
and coffee, *324
and coma, *525
in elderly patients, *348
and glucagon response to glucose, *312
and growth hormone response to arginine, *772
and hexosemonophosphate shunt, *309
and hypernatremia, 579-581
and hyperosmolarity, *231
in infants of diabetic mothers
and epinephrine release, *292-293
and insulin-treated rats, 244-250
and islet β-glycosidases, *409
and islet cell adenoma, *717
and neuromuscular changes, *590
and nonthiazide diuretics, *528
in obese mice, *593
and insulin-glucose relationships, *324-325
and pancreatitis, 437
and pregnancy, *347
and rat fetuses, 367
and red blood cells, *653
reduced insulin B-chain induced
and pituitary and adrenal influence, 67-71

HYPERGLYCERIDEMIA
and carbohydrate, 104
carbohydrate-induced
and lipid distribution in gingival tissue, *650
and insulin response, 80

HYPERINSULINEMIA, *299
and diazoxide, *406
and free fatty acids, *409
and hepatic cirrhosis, *340
and hypertriglyceridemia and coronary heart disease, *343
and obesity, *315, *591
in children, 267
in diabetic Pima Indians, *291
and hypoglycemia, *323
without hypoglycemia, 749-750

HYPERKETONEMIA
sodium chloride-induced, *588

HYPERLACTATEMIA
and phenformin, *654

HYPERLIPEMIA
"carbohydrate-induced," *649
and ethanol, *306
and glucose loading study, 560, 563-564
and obese children, 261
and pancreatitis, 437

HYPERLIPIDEMIA
and clofibrate, *651

HYPERMETABOLISM
and plasma glucose and fatty acid response, *778

HYPERNATREMIA
and glucose intolerance, 579-581

HYPERPHAGIA
and obese children, 261

HYPERPOLARIZATION
of skeletal muscle
and insulin, *589

HYPERTENSION
in diabetes survey, 223
and endometrial carcinoma, *469
and fetal survival, *291
and insulin requirement, 165-166
and juvenile diabetes, *591
prevalence, *114

HYPERTHYROIDISM
and carbohydrate metabolism, *345

HYPERTRIGLYCERIDEMIA
carbohydrate-induced, *777
and hyperinsulinism
in young coronary heart disease patients, *343
and insulin response, *174
and pancreatectomy, *345-346

HYPOGLYCEMIA
and adipose tissue extracts, *314-315, 489-491
and adrenocorticotropic hormone deficiency, *410
aryl sulfonylurea induced, *316
and central nervous system damage, *772
corticotrophin-induced, *526
and diazoxide, 256
and extrapancreatic tumors, *411
and free fatty acids, *409
and gastric cancer, 286
and growth hormone response, *171, 610
in myxedema, *407
and pregnancy, *527
and hepatic glucose release, *233
and hepatitis, *56
idiopathic, *652
and synalbumin insulin antagonism, 557-559
and tolbutamide tolerance, *113
infantile
and diazoxide, *173
insulin-induced
and beta-adrenergic receptors, 141
and growth hormone secretion, *116
and insulin secretion study, 84
investigation model for, *524
and islet-cell tumors, *654
leucine-sensitive, 170-171, *589
and diazoxide treatment, *406-407
and liver glycogen, 15
and 1-methyl-4-pyridinium chloride, 646-647
and monoamineoxidase inhibitors, 628-633
neonatal
etiology of, *412
and obesity and hyperinsulinism, *323
and oral hypoglycemics, 166-167
and pancreatectomy, *57
and pituitary function, *588
and plasma cortisol response, 124-126
and renal failure, 166-167
and Rh-erythroblastosis fetalis, *113
ribose-induced, *713
and starvation
in newborn pigs, *593
and streptozotocin and nicotinamide, 761-764
and sulfonylureas, *593
and neurological complications, 522
and tolbutamide degradation, *717-718
in twins, *173

HYPOINSULINISM
and hyperinsulinism, 750

HYPOPHYSECTOMY
and carbohydrate tolerance, *175
and C-14-glycogen deposition, 373-374
and diabetic retinopathy, 123, *232, *528, 634-635
and glucokinase, *300-301
and growth hormone response, *528
and retinitis proliferans, *318
and hormonal control of ketosis in rats, *300
and hyperglycemia, 67-71
and insulin-induced hyperpolarization of muscle, *589

HYPOPITUITARISM
and arginine, *115
and diabetes
and growth hormone, *654
and dwarfism
and growth hormone effect on carbohydrate metabolism, *525
and growth hormone, 667, 672
and insulin sensitivity, 147-150

HYPOTHALAMUS
and Cushing's disease, *653
and gold thioglucose, *408
lesions
and glucose and fatty acid utilization, *301

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

HYPOTHERMIA
and insulin release
and adrenergic regulation, *298-299

HYPOTHYROIDISM
and carbohydrate metabolism, *345
and diabetes, *409
and growth hormone level, 672
and growth hormone response to insulin, *115
and plasma growth hormone, *526

I

IMIDAZOLE
and insulin secretion, *308

IMMUNOGLOBULIN-G
and diazoxide therapy, *170

IMPOTENCE
and diabetes, 272, *349-350

INCRETIN, *779

INFANTS
big
and maternal plasma insulin response, 37-46
and carbohydrate metabolism, *412
deformed
and insulin antagonism, *58
of diabetic mothers
and placental microscopy, *406
and erythroblastosis fetalis, *51
and galactosemia detection, *53
and glucose, free fatty acids, and growth hormone, *55
and glucose loading, *524
and glucose tolerance tests
and capillary blood values, *321
and hyperglycemia
and epinephrine release, *292-293
and hypoglycemia
and Rh-erythroblastosis fetalis, *113
and synalbumin insulin antagonism, 557-559
hypothermic
and insulin release, *298-299
malnutrition
and chromium and carbohydrate metabolism, 645
newborn
and islet cell adenoma, *717
and islet cell tumor, *652
urine insulin excretion in, *526
premature
and plasma insulin, glucose, and free fatty acid response, *306
survival
and pregnancy complications, *291

INFECTION
and diabetes onset, *316
and glucogenesis, *775
and juvenile diabetes, *335, *774
staphylococcal, 227

INFRARED THERMOGRAPHY, *230

INSULIN
"abnormal," *592
absorption
and small intestine, 625-627
and acromegaly, *525
action, *525-526
in adipose tissue cells, *330
and chromium, 678
and growth hormone, *333
inhibition in muscle, *58
on skeletal muscle, *304
and adipose tissue, *234
and adrenalin
and tolbutamide, *350
adsorption
by infusion, 766-770
allergy
and lymphocyte transformation test, *341
alpha and beta chain
and chromatography, *590
in diabetics, 547-555
immunoassay, *347
radioimmunoassay, 61-65
reduction, *718
and amino acid incorporation into liver proteins, *772
and ani muscle, *229
antagonism
and cleft lip and palate, *116
and congenital deformities, *58
and hypoglycemia, 557-559
and insulin β chain-albumin complex, 1-7
B-chain
and hyperglycemia studies, 67-71
-binding antibodies, *714
bioassay
and serum dilution and cortisol antagonism, *714-715
biosynthesis, 725-735, *774, *778
in fetal bovine pancreas, *294
and proinsulin, *309
in rat, *309-310
"bound"
and human serum, 369-373
and insulin disposition in perfused rat heart, 427
bovine
cleavage studies, *717
coypu
and guinea pig, 8-11
and creatinuria prevention, *654
crystalline
and "bound" insulin, 427-435
and cyclic 3',5'-adenosine monophosphate metabolism, *711
deficiency
and fatty acids, 423-424
and gold thioglucose-induced lesions, *408
and juvenile diabetes, 27
and liver glycogen level, 13
and nicotinic acid, 353-360
and sugar transport, 673-677
dependence
and coma, *525
deprivation
and free fatty acid turnover, *317
and rat liver glucokinase, 611-615
and diazoxide, *170
disappearance
and growth hormone, *112
discovery of, 600-603
dosage
and adsorption to laboratory glassware, 768-770
and glycerol, *291
and urine tests, 284
and endogenous hypertriglyceridemia, *174
exogenous
and fatty acid synthesis and glucose C-14 utilization, 362-367
and fetal growth and biochemical composition, *411
in fetal pancreas cultures
and glucose, *651
in fetal plasma and fluids of sheep, *588
fluoresceinthiocarbamyl
preparation and properties of, *468
in gallbladder bile, *55
and glucagon, *340
and glucose-C-14 conversion by fibroblasts, *326
and glucose metabolism, *409, *655
-glucose ratio, *323-324
-glucose relationships
in obese hyperglycemic mice, *324-325
and glucose transport, *57
and glucose uptake
and exercise, *412
and glucose-U-C-14 metabolism, *525
and glycogen synthesis, *471
and growth hormone, 667, 672
and 2-deoxy-D-glucose, *176
release, *174, *716-717
and hexosamine content of alloxan diabetic rabbit vitreous humor, 105
homeostasis
and submaxillary salivary glands, *325-326
and hyperchylomicronemia, *346
hyperglycemia and hyperosmolarity, *231
and hypopituitarism, *116
immunoassays, 133-135, 187-188, *526, 537-545
of gastric cancer, 286-289
and pancreas β-cell morphology, *306-307

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

and proinsulin, *777
immunology and biology, *231
immunoreactive, *408
and obesity, *315
and pancreatitis, 440
-induced hyperpolarization of muscle, *589
induced hypoglycemia
and beta-adrenergic receptors, 141-145
inhibition
and plasma albumin, 374
international standard, 705-707
iodinated, *650
levels
and hypothalamic lesions, *651-652
in perfused rat pancreas-duodenum preparation, *338
in pregnancy, *293-294
-like activity, *652
and adipose tissue, *53-54
in arterial serum and lymph, 669-670
assays, *116, *408-409
in human serum, 369-373
nonsuppressible, *313
-like properties
of p-chloromercuribenzene sulfonic acid on fat cells, *303-304
and lipolysis, *230, *304-305
and liver carbohydrate metabolism, *336
and liver glycogen synthesis, *408
and liver metabolism, 244-250, 251-255, *711
and lung, *777
metabolism and excretion
and kidney, 161-167
microradioimmunoassay, *337
and milk production, *114
new component of, *310
and nucleic acid synthesis, *172
pancreatic
in severe erythroblastosis fetalis, *51
and pancreatitis study, 437-443
passage, 668-671
across vascular beds, *339
in liver cell, *652-653
and phenylethanolamine-N-methyl transferase, *470
physiology and chemistry, 604-608
and plasma cortisol response, 124-126
and plasma free fatty acid, *114
and plasma growth hormone in pig, *527
porcine and bovine
proton magnetic resonance spectra, *229
-precipitating antibodies, *592
and proinsulin, 737-738
properties, *773
and protein synthesis, *58, *173, *316
and prothrombin response to anticoagulants, *779
radioimmunoassay
and subdiabetes, *176
release
and alpha-cell secretions, *330-331
and amino acids, *171
and arginine infusion during pregnancy, *347
and blood glucose, *111
and carbohydrate metabolism, *710-711
early phase, 685-691
and glucagon, *311-312
and glucose concentration, 187-192
and glucose metabolism, *406
and hyperglycemia, 475-479
and hypothermia, *298-299
and insulomas, *343
kinetic factors, *712
and pheochromocytoma, *318-319, *593
and potassium, *57, *713
and secretin, *655
replacement
and pancreas beta cell changes, *407
requirements
and remission of juvenile diabetes, *406
reserve
in children with chemical diabetes, *336-337
and juvenile diabetics, *326
resistance, *173, *315, *407
and gigantism, *655
and insulin antibodies, *776-777
and juvenile diabetes, *291
response
in adolescent obesity, *342
and basal insulin levels, *290
and cirrhosis, *317
and diet, 72-74, *323
to glucagon, *297
to glucose, *468, *527-528, *712
and glucose administration methods, *338-339
and growth hormone, *525
and oral contraceptive agents, *307, *307-308
to oral glucose load, 560-569
and Pima Indians, *291
and prediabetes, *350
and protein, *297
and RNA transcription, *329
secretion
and ACTH, *173
and adenylcyclase, *234
and amino acids and glucose, *524-525
and aminophylline, *292
and bronchial carcinoid tumor, *471
and calcium, *468-469
and cholinergic and adrenergic substance, *55
and cholinomimetics, *308-309
and diazoxide, *772
and epinephrine, stress, and exercise, *718
and estrogen, *590
and ethanol ingestion, *298
and exercise, 209-216
and free fatty acids, *409
and glucagon and secretin, *651
and growth hormone, 661-666
and hormones, *172, *775-776, *779
and imidazole, *308
by insuloma and normal pancreas slices, 83-88
and intestinal hormones, *592
and liver disease, *327
and mannoheptulose, *527
measurement of, 641-643
and medium chain triglycerides, *347-348
and metabolism study in dogs, *348-349
and myotonic dystrophy, *233
and new hypoglycemic agent, *294
and obesity, *54-55
and obesity and juvenile diabetes, *320-321
by pancreas of sand rat, 752-759
and pancreatic blood flow, *333-334
and pulse administration of glucose, *53
and sodium and potassium, *713
and tolbutamide therapy, *344
and tranylcypromine, 617-623
and xylitol, *231
sensitivity
and alloxan diabetic rats, *411
and carbohydrate intolerance and obesity, *656
in depressed patients, 629-630
and glucose tolerance, *715-716
and hexokinase, *526-527
and hypopituitarism, 147-150
and pregnancy, *527
shock treatment, *172
and sodium salicylates, *471
stability
and storage temperature, *311, 499-502
and sugar transport in muscle, *304
synthesis, *54, *526, *774-775
chemical, *656
and nucleic acid metabolism, *778-779
and synthetic alpha and beta chains, *292, *410
tolerance tests
and mebanazine, 628-633
and urea formation, *655
urinary
in newborns, *526
utilization
by proteins of organs and tissues, *591
in venous and arterial blood, *777

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

withdrawal
and hypophysectomy and pancreatectomy, *300
and plasma triglyceride removal, 127-131
zinc
oxidation, *112

INSULIN-I-125
action in mouse liver and kidney, *406
binding properties, *649

INSULIN-I-131
adsorption by laboratory glassware, 766-770
in pancreatitis study, 437-443
in perfused rat heart, 429-432, 434-435

INSULINOPENIA
measurement of, *344

INSULITIS, *593

IRRADIATION
and retinopathy, *318

ISLETS OF LANGERHANS
beta cells granulation
and glucose and epinephrine, *322-333
and biosynthesis of insulin, 725-735
hyalinization
and sulfonylureas, 505-507
and hyperglycemia, 475-479
innervation, 33-35
and insulin biosynthesis in rat, *309-310
and insulin and glucagon release
and glucose concentrations, 187-192
and insulin release
and glucagon, *311-312
and potassium, *713
and insulin secretion and glucose phosphorylation
and mannoheptulose, *527
and mammosomatotropic tumor, *308
secretion granules, *313
and sugar oxidation, *470
and sugars, *713
and sulfonylurea therapy, 507
and tumors, 582-587
and vagus nerve stimulation, *308-309

ISOCITRIC DEHYDROGENASE, 614

ISOENZYMES
of adenosine triphosphate, *113
hexokinase, *409

ISOPROTERENOL
and beta-adrenergic blockade, 142-145
and insulin release, *55

ITALIANS
and diabetes, *114

K

KETOACIDOSIS
and cerebral edema, diabetes insipidus, and sudden death, 108
and gastric mucosa study, *319
and pancreatitis, 437
and pituitary gland removal, *525
and thyroiditis, *230

KETOGENESIS
and glucagon, theophylline, and cyclic AMP, *329

KETONE BODIES
and cardiac glycogen determination, *589-590
and free fatty acid release, *54
and octanoate, 201-202
splanchnic
and nicotinic acid, *230

KETONEMIA
and diet, *174

KETONURIA
and diabetic acidosis, *777-778

KETOSIS
in diabetes survey, 222
and glucose oxidation, 94
and hormonal control, *300
and liver glycogen, 13
and obesity, *339
prevention, *291

KETOSTIX STRIPS
evaluation study of, 398-401

KIDNEY
biopsies
and pituitary stalk section, *319-320
changes
and sorbitol pathway, *300
disease, *650
and bladder dysfunction, *321
and diabetes survey of Chinese, 225-226
and fetal survival, *291
and insulin requirements, 165-166
function
and diabetes control, *408
glomerular lesions
in diabetic mice, *301
and glucagon, *173
gluconeogenesis
and hormones, *348
and metabolic acidosis, *778
glucose output
and starvation, *305
glucose threshold, *779
and insulin, *406
and juvenile diabetics, *171
and microangiopathy, 391-392
pantothenic acid, *292
tubular secretion of L-glucose, *469
uric acid clearance
and glycogen storage disease, *470

KIMMELSTIEL-WILSON SYNDROME, 220

KWASHIORKOR
and glucose, free fatty acid, and insulin interrelations, *171-172

L

LACTALBUMIN, 436

LACTATE
and biguanides, 101
dehydrogenase
in obese-hyperglycemic mice, *53
and liver urea formation, *411
and oleic acid, 196

LACTOSE
intolerance
and celiac disease, *776

LESIONS
aortic
in primates, 368, 397
arteriolar, *171
eye
and dietary chromium, 512
gold thioglucose-induced
and diabetes, *408
hypothalamic
and glucose and fatty acid utilization, *301
and growth hormone and insulin levels, *651-652

LEUCINE
incorporation into proteins, 737
and insulin biosynthesis, *778
and insulin release, *171
and islet cell adenomata, 87
-sensitive hypoglycemia, *589
sensitivity, *170
and diazoxide treatment, *406-407

H-LEUCINE
incorporation
and proinsulin biosynthesis, *294

LIPEMIA
and carbohydrate tolerance, *649
diabetic, *111-112

LIPIDS
and biguanides, 101
and carbohydrates, 12
in gingival tissue
and hyperglyceridemia, *650-651
membrane permeability
and valinomycin, *290, *412
and rat fetus studies, 363
synthesis
and carbohydrates, *291
in insulin-injected rat fetus, *411
of rat adipose tissue, *528

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

LIPOGENESIS, *51
and adipose tissue, *335
insulin-stimulated, *116
and prolactin, *113

LIPOLYSIS
and adrenalin and theophylline, *341
and antilipolytic agents compared, *304-305
and cations, *304
and insulin, *230
and insulin-like activity, *54
and sulfonylureas, *50

LIPOPROTEIN
deficiency, *51-52, *53
and fat transport, *51
lipase
and triglyceride, 127-131

LITHIUM
and insulin secretion, *713

LIVER
and alloxan diabetes, 106-107
and diazoxide, 256-259
carbohydrate metabolism
and insulin, *336
cirrhosis, 226-227
and Chinese diabetics, 226
and glucose tolerance, free fatty acids, and insulin responses, *317
and hyperinsulinism, *340
and medium chain triglycerides, *347-348
disease
and diabetes, *172
and fatty acid synthesis, *113
free fatty acid release and ketogenesis
and glucagon, theophylline and cyclic AMP, *329
and gastrointestinal hormones, *330
glucokinase, *409
hormonal control of, *300-301
and insulin deprivation, 611-615
gluconeogenesis
and carbohydrates, *291
glucose regulation of, *717
and insulin, *231
glucose output
and caffeine, *350
and glucose release, *111, *233
and glucose loading, 418
glycogen
of diabetic animals, 252
and diet, *174
and insulin, 246
glycogen metabolism
in azotemic rats, *337-338
glycogen synthesis
and glucose, cortisol and insulin, *408
glycogenesis
and stress, *115
glycogenolysis
and aryl sulfonylurea drugs, *316
granulomas
and sulfonylurea therapy, 507
hepatitis
and hypoglycemia and hemorrhage, *56
and insulin, growth hormone, and glucose, *327
and insulin passage, *652-653
lipase
and glucagon, *776
lipid metabolism
and diabetes, *176
lipids
and carbohydrate incorporation, 12
and nicotinic acid, 356, 357-358
metabolism
and diabetes, 244-250
pantothenic acid, *292
perfused
amino acid uptake study, *320
and insulin, 251-255
and urea formation, *655
protein synthesis
and oral hypoglycemics, *588
proteins
and amino acid incorporation, *772
rat
and gluconeogenesis inhibition, 194-205
urea formation
and pyruvate, *411
and Wilson's disease, 269, 285

LUNGS
in Chinese diabetics, 227
hexokinase
and alloxan diabetes, *526-527
and insulin, *777
tuberculosis
in diabetes survey, 227

LYMPH
and insulin-like activity, 669-670

LYMPHOCYTE TRANSFORMATION TEST, *341

LYMPHOCYTIC THYROIDITIS
and diabetes, *230

M

MAGNESIUM
and glucose tolerance, *589
and pregnancy, *718
and sugar transport in muscle, 673

MALABSORPTION SYNDROME
and gastrectomy, 132, 146

MALNUTRITION
and chromium and carbohydrate metabolism, 645
and gastrectomy, 146
and growth hormone, 610

MANNITOL
and muscle permeability, *304

MANNOHEPTULOSE
and glucose, *234
and glucose phosphorylation and insulin secretion, *527
and insulin and glucose release, 190
and insulin release study, *406
and potassium deficiency, *715

MARASMUS
and glucose, free fatty acid, and insulin interrelations, *171-172
and mental development, 771

MATERNAL DEPRIVATION SYNDROME
and growth hormone level, 672

MEBANAZINE
and hypoglycemia, 628-633

MENINGITIS
and pituitary ablation, *294

MENSTRUATION
and glucose tolerance, *714

MENTAL ILLNESS
and anorexia nervosa, 683
and juvenile diabetes, *317-318
and monoamineoxidase inhibitors, 628-633

MENTAL RETARDATION
and hypoglycemia, *170
and nutritional marasmus, 771
and serum insulin, *589

METABOLISM
and alloxan diabetes and streptozotocin-induced diabetes, *592
and anorexia nervosa, 683
and biguanides, 96-102
carbohydrate
in biotin-deficient rats, *772
and chromium, *407-408
and diazoxide, 256-259
and hypernatremia, 579-581
and hypopituitary dwarfs, *525
and insulin, *336
and insulin release, *710-711
and insulin treatment, *172
and islet cell tumor, *652
and kwashiorkor and marasmus, *171-172
and leukocyte pyruvate kinase, *331
in normal newborns, *412
and oral contraceptives, *344-345
and thyroid disease, *345
carbohydrate and fat
and pheochromocytoma, *593
and serum insulin response, *591
carbohydrate and lipid
and progestin, *341-343

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

carbohydrate and potassium
and diabetes, *230
chromium and carbohydrate
and infant malnutrition, 645
copper
and Wilson's disease, 269
cyclic 3',5'-adenosine monophosphate
and insulin, methyl xanthines, and nicotinic acid, *711
and diazoxide, *349
and diet and weight, *528
fatty acid, 202-203
fructose
and glucagon, *776
and gastrointestinal hormones, *330
glucose
and alloxan diabetes, *411
and anti-diphtheroid sera, *331
and brain tissue, 90-94
in fat cells, *655
glucose-2-T as a tracer for, *54
and insulin, *406, *409
and norepinephrine, growth hormone, and fasting, *290
and pregnancy, *291
glucose and fatty acid
and hypoglycemia with extrapancreatic tumors, *411
and sodium β- hydroxybutyrate, *229
glucose, oxygen and carbon dioxide
in skeletal muscle, *649
and glucose tolerance studies in dogs, *348-349
glucose-U-C-14
in adipose tissue, *525
growth hormone and insulin
and acromegaly, *525
and glycerol, *291
glycogen
and azotemia, *337-338
insulin
and acromegaly, *525
islet cell
and sugars, *713
of isolated fat cells, *174
and nicotinic acid
and insulin deficiency, 353-360
in normal and alloxan-diabetic rat livers, 244-250
and obesity and hyperinsulinism, *315
and starvation
and reserpine, *312
steroid
in diabetes, *407
sugar
and pancreas islets, *774
and tolbutamide therapy, *779

METFORMIN
and chlorpropamide comparison, *524
and metabolism, 96-102

METHIONINE
in groundnuts, 556

METHOXAMINE
and beta-adrenergic blockade, 142-145

3-O-METHYL-D-GLUCOSE
transport, *524

1-METHYL-4-(3-METHYL-5-ISOXAZOLYL) PYRIDINIUM CHLORIDE, 646-647

I-METHYL-I-NITROSOUREA, 760

5-METHYLPYRAZONE-3-CARBOXYLIC ACID
and free fatty acids, *292

METHYL XANTHINES
and cyclic 3',5'-adenosine monophosphate metabolism, *711

MICROANGIOPATHY
diabetic, 388-394
and family history, *412
and rectal mucosa capillaries, *592

MICROSCOPY
electron
and conjunctival microaneurysms, *303
and diabetic neuropathy,* 468
of gastrointestinal mucosa, *293
and insulin synthesis, *774-775
of islet-cell tumors, 582-587
and microangiopathy, 388-389
of pancreas beta cells, *306-307, *589
of innervated islet cells, 34-35
of pancreas cells, 153-159, 756-757
phase contrast
and diabetic placenta, *406

MINERALS
chromium
and carbohydrate metabolism, *407-408
and eye lesions, 512
and glucose tolerance, *411, 678
in hair of normal and diabetic children, 517-519
and hyperglycemia, *777
copper
and Wilson's disease, 269, 285
iron
and diabetes, *468
potassium
and hyperglycemic agents, *715
and insulin release, *713
permeability, *412
transport and glycolysis, *301-302
sodium
permeability, *412
sodium and potassium
and insulin secretion, *713

MONOAMINEOXIDASE INHIBITORS
and hypoglycemia, 628-633

MONONEUROPATHY MULTIPLEX, *655-656

MONOSACCHARIDES
malabsorption. *233
transport in Ehrlich ascites tumor cell, *410

MORTALITY
and cardiovascular diseases, *56
of diabetic amputees, 520-521
of diabetics in Hong Kong, 220
and hypophysectomy, *232
infant
and pregnancy complications, *291
and ketoacidosis, 108-109
and kidney disease, *650
and long-term sulfonylurea therapy, 503-507
and myocardial infarction, *338
perinatal
and diabetes and prediabetes, *410
and glucose tolerance, *291
and postoperative shock, *468
and pregnancy in juvenile-onset diabetics, *334

MOUTH
cleft palate and lip
and insulin antagonism, *116

MUMPS
and diabetes onset, *316

MUSCLE
contractions
and metabolism, *649
exercise
and insulin secretion, 209-216
gastrocnemius
glyceride and phospholipid concentrations, *50-51
glucose utilization, 1-7
insulin action, *58
and insulin-induced hyperpolarization, *589
ribosomes
and protein synthesis, *58
and serum insulin and glucose uptake, *650
skeletal
and insulin action, *304
sugar transport
and magnesium deficiency, 673-677

MYOCARDIAL INFARCTION, 220
prevalence, *114
in young diabetics, *338
in young patients, *343

MYOCARDIUM
glycogen determination, *589-590
ischemia, 223

MYOTONIC DYSTROPHY
and insulin secretion, *233

MYSTECLIN-F, 386-387

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

MYXEDEMA
and growth hormone response to hypoglycemia, *407

N

NAVAJOS
and diabetes, *776

NEPHROPATHY
in diabetes survey, 225-226

NEPHRECTOMY
and insulin metabolism, 162
and microangiopathy, 388
and sulfonylurea, 505-507

NEPHROSIS
and insulin metabolism, 162

NERVOUS SYSTEM
autonomic
and insulin secretion, *334
damage
and hypoglycemia, *772
and diabetic diarrhea, *653
and hyperglycemia, *590
and islet-cell innervation, 33-35
and juvenile diabetes, *114
laryngeal nerve
and diabetic neuropathy, *302
and long-term diabetes, *294
mononeuropathy multiples, *655-656
paralysis
and shellfish poisoning, 36
sciatic nerve
and diabetes, 239-243
touch perception
and blind diabetics, *302

NEUROPATHY, DIABETIC, *112, *113, *486
and clofibrate, *651
in diabetes survey, 224-225
and diphenylhydantoin, *322
and esophageal dysfunction, *172, *322, *334
gastric, *412
and impotence, *349-350
and laryngeal nerve involvement, *302
short-term prognosis, 270-273
of upper extremities, *773

NICOTINAMIDE
and plasma glucose, 760-764

NORADRENALINE
and islet-cell innervation, 35

NOREPINEPHRINE
and free fatty acids and glucose metabolism, *290
and gluconeogenesis, 620
and insulin release, *55, 617

5-NUCLEOTIDASE
and glucagon, *292

NUTRITION
and anorexia nervosa, 683
and groundnuts, 556
and growth hormone response, *528
and marasmus and mental development, 771

O

OBESITY
in adolescents
and insulin response, *342
and arginine
and serum insulin and growth hormone, *50
and cyclamate utilization, *346
and diabetes, *112, *323
and diabetic ketosis, *339
and endometrial carcinoma, *469
and free fatty acids and glucose metabolism study, *290
and glucose loading study, 560, 563-564
and glucose metabolism
and phenformin, 481-488
and hyperglycemia, *593
and hyperinsulinism, *315, 750
and hyperinsulinism
in Pima Indians, *291
and insulin-glucose relationships, *324-325
and insulin release, 685-691
and insulin response, *290
to glucagon, *297
to glucose, *712
and insulin secretion, *54-55, *56-57
in diabetic children, *320-321
and insulin sensitivity of adipose tissue, *656
and islet β-glycosidases, *409
and plasma glucose, free fatty acids, and immunoreactive insulin, 261-268
and pregnancy
and glucose tolerance, *291
prevalence, *114
and serum insulin response, 25, *591

OCTANOATE
and glucose and ketone body production, 201

ORAL CONTRACEPTIVES
and carbohydrate metabolism, *344-345
and glucose and insulin alterations, *592
and glucose tolerance, *341-342, *590
and subclinical diabetes, *307, *307-308

ORAL HYPOGLYCEMIC AGENTS, *174-175. *See also* Sulfonylureas
and blood cholesterol, triglycerides, and body weight variability, *325
and calorie intake, 522
historical background, 604
and juvenile diabetes, 27
and liver protein synthesis, *588
and mechanism of diabetes, *407
and metabolism, 96-102
1-methyl-4-(3-methyl-5-isoxazolyl) pyridinium chloride, 646-647
new, *294
and potassium deficiency, *715
single and combined therapy, *314
therapy study, 503-507
tranylcypromine, 617-623

OSTEOPOROSIS
in Chinese diabetics, 228

OXYGEN
consumption
and carbohydrates, *53

OXYTOCIN
and insulin secretion and neurophypophysial, *172

P

PALMITATE
and glucose oxidation, 90-94

PALSY
in diabetes survey, 224-225

PANCREAS
alpha cells
and insulin, cortisone, and tolbutamide, 152
beta cells
and adrenalin action, *350
and chronic insulin replacement, *407
and cortocotrophin-induced hypoglycemia, *526
and glucagon and tolbutamide, 135
and glucose and tolbutamide, *589
morphology and insulin immunoassay, *306-307
and premature infants, *306
and proinsulin, 744-745
and sugars, *713
blood flow
and insulin secretion, *333-334
disease
and diagnosis, *772-773
fetal
and glucose effect on insulin content, *651
and insulin secretion, 362-367
and insulin synthesis, *294
and gastrointestinal hormones, 300
glucagon
and enteric glucagon-like immunoreactivity, *321-322
and glucose, *312
homografts
endocrine function, 332, *715
in pregnancy, *293-294

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

hyperplasia
insulin secretion
and multiple endocrinal adenomata, 83-88
insulin storage
and chronic insulin replacement in rat, *407
and ischemic pancreatopathy, *712
islets
adenoma, *299, 507, *717
beta glycosidases, *409
carcinoma, *327
and enzyme activities, *524
and ethanol, *298
and glucagon, *292
and glucose metabolism and insulin release, *710-711
and glucose tolerance, *291
innervation, 33-35
and insulin release, *406
and insulin synthesis, *774-775
lactate dehydrogenase, *53
mitotic activity, *306
and sugar metabolism, *774
tumors, 582-587, *654, 663-665
and magnesium deficiency, *718
perfused
and insulin and glucose levels, *338
and insulin secretion, *468-469, *712
rabbit
and insulin secretion, *713
sand rat
and insulin secretion, 752-759
scanning, *717
and tranylcypromine, 622

PANCREATECTOMY
and ACTH and growth hormone study, *290
and dietary fat and serum lipids, *342-343
and endogenous chylomicronemia, *345-346
in goose, *57
and hormonal control of ketosis in rats, *300
and insulin absorption, 625-627
and insulin secretion study, 184-185
and metabolism study in dogs, *348-349

PANCREATITIS
and Chinese diabetics, 226
and diabetic coma, *774
diagnosis, *717, *772-773
and insulin metabolism, 437-443

PANCREOZYMIN
and insulin secretion, *592

PAROTID GLAND
enlargement
and Chinese diabetics, 226

PENICILLAMINE, 269, 285

PENNSYLVANIA
myocardial infarction, hypertension, diabetes, and obesity study in, *114

PENTAGASTRIN, *233
and insulin secretion, *653-654

PEPTIDES
synthesis, *54

PERU
marasmus study in, 771

PHAGOCYTOSIS
and diabetes, *335

PHENELZINE
and hypoglycemia, 628-633

PHENFORMIN, *112
and alcohol and hyperlactatemia, *654
and glucose metabolism
and obesity, 481-488
and lipolysis, *304-305
and metabolism, 96-102

PHENFORMIN HYDROCHLORIDE
and hypercholesterolemia, *711

PHENOLPHTHALEIN
and glucose transfer, *773

PHENTOLAMINE
and hypothermia, *298-299

PHENYLALANINE
incorporation into proteins, 737
in proinsulin, 725

PHENYLETHANOLAMINE-N-METHYL
transferase
and insulin and glucose, *470

PHENYRAMIDOL
and tolbutamide metabolism, *175

PHEOCHROMOCYTOMA
and carbohydrate and fat metabolism, *593
and insulin release, *318-319

PHLORETIN
and glucose transfer, *773

PHLORIDZIN
and glucose production
and D-ribose, *713
and L-glucose secretion by kidney, *469
and insulin release study, *406

PHOSPHOFRUCTOKINASE, 614
and citrate, 204

PHOSPHORYLASE
and diazoxide, 259

PIMA INDIANS
and hyperinsulinism, *291

PITUITARY GLAND
ablation
and diabetic retinopathy, 123, *294, *528
and anorexia nervosa, 683
cryoablation
and diabetic retinopathy, 634-640
and growth hormone response, *528
insufficiency
and retinopathy, *318
and ketoacidosis, 109, *525
sensitivity to hypoglycemia during pregnancy, *347
stalk section
and renal biopsy study, *319-320
suppressive therapy, *318

PLACENTA
cellular growth, *234
and gestational diabetes, *406
premature separation of
and fetal survival, *291

PLASMA
acetoacetate
and Ketostix, 398-401
albumin
and glycolytic intermediates in rat diaphragm muscle, 374
and insulin inhibition, 746-751
amino acid
and glucose, *57
and insulin, 247
amino acid nitrogen
and cortisol, *711
cortisol
and diabetes, *408
response to insulin and circadian rhythm, 124-126
cortisol and growth hormone
assays, *655
free fatty acids
and fetuses, *115-116
and glucose utilization, *528
and growth hormone, *528
and juvenile diabetes, 29
and 5-methylpyrazone-3-carboxylic acid, *292
and nicotinic acid, 353-360
and plasma glucagon and serum insulin, *715
and tolbutamide, *779
free fatty acids and glucose
during labor, *176
free fatty acids, glycerol, and ketones
and diet, *56
glucagon-degrading activity, 183
glucose
and cardiac glycogen determination, *589-590
and fetuses, *115-116
and streptozotocin and nicotinamide, 760-764
glucose and fatty acids
and hypermetabolism, *778
and pancreatitis, 440-443

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

glucose, free fatty acids, and immunoreactive insulin
and obese children, 261-268
glucose and insulin
and cold exposure and starvation, *335
and ethanol ingestion, *298
and glucose infusions, *524
glucose response
in healthy subjects, *319
growth hormone
and acromegaly, *113
and arginine infusion, *114-115
and blood sugar, *233
in childhood, 610, 667, 672
and hypoglycemia, *115, *171
and hypothyroidism, *526
and insulin, *527
and juvenile diabetes, 28-29
insulin
and acromegaly, *470
and caloric intake, *232
and fatty acids, *653
and glucose tolerance, *409, *773-774
and idiopathic infant hypoglycemia, 558
immunoassay, 444-457
immunoreactive, *233
and intestinal hormones, *653-654
in nondiabetic, diabetic, and high risk potential diabetes, 547-555
and oral contraceptives, *592
and plasma glycerol triglyceride and free fatty acid levels, 76-81
radioimmunoassays, 61-65, *310
response in juvenile diabetics, 28
and D-ribose, *774
in sheep fetus and fetal fluids, *588
and tolbutamide and glucagon, 133-135
insulin and glucose
and starvation, *469
insulin, glucose, and free fatty acid response to stimuli
in premature infants, *306
insulin and growth hormone
and proteins, *175
and starvation and glucose loading, *714
insulin-like activity
nonsuppressible, *313
insulin response
and chlorpropamide, *650
and meal size and frequency, 72-74
and mothers of heavy infants, 37-46
insulin response to glucose
and oral contraceptive agents, *307-308
lipids
and diabetic retinopathy, 458
lipids and glucose
in normal, diabetic, and cardiovascular disease patients, *411
maternal and cord
glucose, free fatty acids, and immunoassayable growth hormone, *55
sugar
and diet, *323
triglyceride
and diabetes treatment, *470
triglyceride and cholesterol
and nicotinic acid, 359

POLYDIPSIA, 147
and obese children, 261

POLYPEPTIDES
diabetogenic, *591

POLYPHAGIA, 147

POLYURIA, 147

PORTAL VEIN
immunoreactive glucagon, *340

POTASSIUM
deficiency
and ketoacidosis, 108-109
and glucose tolerance, *57
metabolism
and diabetes, *230

POTASSIUM CHLORIDE
and ketoacidosis, 109

POTASSIUM SULPHATE, 269, 285

PREDIABETES
and acromegaly, *470
clinical observations, *230
and diabetes onset, *649-650
and functional microangiopathy, 392
and growth hormone, *293
and insulin response to glucose, *350
and placentas, *234
and plasma insulin, 547-555
and pregnancy, *410
and serum insulin response, 17-25

PREDNISOLONE
glucose tolerance tests
and subclinical diabetic mothers of heavy infants, 37-46

PREDNISONE
-glucose tolerance
and aging, *714

PREGNANCY. *See also* Pregnancy, diabetic
and arginine infusion
and insulin and growth hormone release, *347
and diabetes onset, 221
and fetal outcome
and glycosuria, *294
and fetal response to insulin, 362-367
and glucose assimilation, insulin, and fatty acid levels, *293-294
and glucose excretion, *56
and glucose metabolism, *291
and glucose tolerance tests, *112
and growth hormone, free fatty acids, and growth hormone, *55
and growth hormone responses to hypoglycemia, *527
and magnesium deficiency, *718
and premature delivery
and fetal survival, *291

PREGNANCY, DIABETIC, *409-410
and fetal survival, *291
and growth hormone responses to hypoglycemia, *527
management, *334
and amniotic fluid analysis, *320
and placenta study, *234
and placental pathology, *406

PROGESTIN
and carbohydrate and lipid metabolism, *341-342

PROINSULIN, *309
biosynthesis, *294
and glucose oxidation and fatty acid synthesis, *310
in human urine and serum, *777
isolation and properties, 725-735
porcine
and adipose tissue, 737-745

PROLACTIN
and lipogenesis, *113

PROPANTHELINE, 386

PROPIONATE
and plasma insulin, *653

PROPRANOLOL
and beta-adrenergic blockade, 142-145
and diazoxide metabolism, *349

PROSTAGLANDIN E
and lipolysis, *231, *304-305
and tranylcypromine response, 622

PROTEINS
biological value assays, 436
from carbohydrate, *174
dietary
in groundnuts, 556
and pulses and beans, 508
and glucose utilization, 1
and insulin release
and mild diabetes, *297
and plasma insulin and growth hormone, *175
and rat fetus studies, 363
synthesis
and diabetes, *58
and insulin, *172
and puromycin and insulin, *316
and vitamin D, 218

PROTHROMBIN
response to anticoagulants
and glucagon and insulin, *779

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

PUBERTY
spontaneous
and dwarfism, *718

PURINE
synthesis
and glycogen storage disease, *470

PUROMYCIN
and glucokinase activity, 612-613
and protein synthesis, *316

PYELONEPHRITIS
among Chinese diabetics, 226
and diabetes survey, 225-226

PYRIDINE NUCLEOTIDES
and albumin, 380

PYRUVATE
and albumin, 380
kinase, 614
and liver urea formation, *411
and oleic acid, 196

PYRUVATE-3-C-14
and hepatic gluconeogenesis, *231

R

RACE
and antithyroglobulin antibodies, 136-139
and serum insulin levels, *328-329

RADIOAUTOGRAPHY
of islet cells of diabetic mice, *306

RADIOELECTROCARDIOGRAPHY
and exercise test, *229

RADIOLOGY
and diagnosis of pancreatic disease, *772-773

RESERPINE, *112
and metabolism during starvation, *312
and tranylcypromine, 621

RETINA
and angiopathy, *656
and diabetes, *232, 388-390
hard exudates, 458-467
lipid thrombi in, *112
mural cell changes, *170

RETINITIS PROLIFERANS, 224

RETINOPATHY, DIABETIC, 388-390, *650
and atromid therapy, 458-467
and hypophysectomy, *232
and hypophyseal stalk section, *318
and juvenile diabetes, *591
and lipid thrombi, *112
and microangiopathy, 388
natural history, *588
and neovascular glaucoma, *327
and pituitary ablation, *294, *528
and pituitary cyroablation, 634-640
and prognosis for vision, 121-213
and survey of Chinese diabetics, 224-225
therapy, *318

RH-ERYTHROBLASTOSIS FETALIS
and hypoglycemia, *113

D-RIBOSE
and glucose turnover, *713
and plasma insulin levels, *774

RNA
and insulin synthesis, *779
in placentas, *234
synthesis
and glucose, *309
and hexokinase, *300-301
transcription
and insulin, *329
turnover
and "abnormal" insulin, *592

S

SALIVARY GLANDS
and insulin homeostasis, *325-326

SCHIZOPHRENIA
and insulin shock treatment, *172

SCHWANN CELLS
and aldose reductase, 241

SCIATIC NERVE
and diabetes, 239-243

SECRETIN
and insulin secretion, *592, *651, *655
and plasma insulin, *653-654

SENECA INDIANS
and glucose and insulin measurements, *324

SEROTONIN
and antabuse syndrome, 679
anti-diphtheroid
and glucose metabolism, *331

SERUM
anti-insulin, 422
and adipose tissue, 741
assay, *58
and metabolism study, 251-255
and nicotinic acid, 353-360
carbohydrates, *778
cholesterol and triglyceride
and aging, *714
and phenformin hydrochloride, *711
dilution
in insulin bioassay, *714-715
fatty acids
and diabetes, *471
free fatty acid and insulin
and Staub-Traugott effect, *346-347
fructose
and sucrose administration, *715
fucose
assay, *471
glycoproteins
and diabetes, *290-291
growth hormone
and gigantism, *655
guinea pig anti-insulin
and *H. Pertussis* vaccine, 513-516
and insulin immunoassays, 537-545
insulin
and acromegaly, *775
and arginine, *50
and diabetic remission, *337
and free fatty acids, *715
and glucose in muscle, *650
and L-leucine, *589
and race, *328-329
response to glucose in genetic prediabetic males, 17-25
insulin-like activity, *408-409, *652, *716
insulin, sodium, potassium, chloride, and acetone
and obesity, *339
lecithins and cephalins
fatty acid composition, *772
lipids
and aging, *714
and diabetes, *412
and dietary fat, *342-343
and starch and sucrose, *777
proinsulin, *777
protein
and carbohydrates, *234
and glucagon immunoassay, 181
and insulin-like activity, *652
protein-bound carbohydrates
and diabetes, *332
response to glucose tolerance tests
and long-term tolbutamide therapy, *344
triglycerides
and glucose, *528
uric acid
and glycogen storage disease, *470

SEX
and anorexia nervosa, 683
and antithyroglobulin antibodies, 136-139
and diabetes, 220, 221, *527
and glucose loading study, 560
and glucose tolerance, *409
and idiopathic intermittent edema of women, *331-332
and triglycerides, *715
of twins in diabetes study, 697, 700, 701
and urinary steroid excretion, *407
and vitiligo, *712

SHOCK
gram-negative
and diabetes, *468

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

SKIN
fibroblasts
and glucose-C-14 conversion, *326
and functional microangiopathy, 390-391
and survey of Chinese diabetics, 227-228

SODIUM ACETATE
and free fatty acid release, *54

SODIUM BETA-HYDROXYBUTYRATE
and blood glucose, free fatty acids, insulin, and ketone bodies, *588
and glucose and free fatty acid metabolism, *229

SODIUM CYCLAMATE
and diabetes, *346

SODIUM NITROPRUSSIDE, 398

SODIUM SACCHARIN
and diabetes, *346

SODIUM SALICYLATES
transport and analgesic action and insulin, *471

SODIUM SUCCINATE
and amino acid incorporation in liver protein, *772

SORBITOL
and amino acid incorporation, *772
and diabetes, *291

SORBITOL DEHYDROGENASE, 239

SORBITOL PATHWAY, 239-243
and cerebral edema, *299-300
in diabetes and galactosemia, *300

SOUTH AFRICANS
diabetes study
and capillary ultrastructure, *303

SPINAL CORD
degeneration
and gastrectomy, 132, 146
and diabetes, 239-243
and long-term diabetes, *294
section
and epinephrine hyperglycemia, *712

SQUIRREL MONKEY
and carbohydrate metabolism and dietary chromium, *407-408

STAPHYLOCOCCAL INFECTION, 227

STARVATION
and glucose levels, *408
and hypoglycemia
in newborn pigs, *593
and insulin absorption, 625-626
and kidney glucose output, *305
and muscle glycerides and phospholipids, *51
and plasma free fatty acid, 424, 426-427
and plasma glucose and insulin levels, *335, *469
and plasma growth hormone, *527
and plasma insulin and growth hormone, *714
and prothrombin response to anticoagulants, *779
and reserpine and metabolism, *312

STAUB-TRAUGOTT EFFECT
and serum free fatty acid and insulin levels, *346-347

STEATORRHEA, 385

STEROIDS
and diabetes, *407
-glucose tolerance tests
and oral contraceptive agents, *307

STILBESTROL
and glucose transfer, *773

STOMACH
and sugars, *293

STREPTOZOTOCIN
-induced diabetes, *592
and mitotic activity of islet cells, *306
and plasma glucose, 760-764

STRESS
and adrenal gland pregnenolone and progesterone, *469
and insulin secretion, *718
and liver glycogenesis, glycogen synthetase, and adrenal responsiveness, *115

SUCCINATE
and liver urea formation, *411
oxidase
and biguanides, 497
and metformin, 102

SUCROSE
and serum fructose levels, *715
and serum lipids
and thyroidectomy, *777

SUGAR
and aldose reductase, 242
and cardiovascular disease, *56
and islet metabolism, *713
oxidation
and islets of Langerhans, *470, *774
and stomach action, *293
transport
into ascites tumor cells, *410
and insulin and magnesium deficiency, 673-677
in muscle, *304
and urine testing, 281-285

SULFITOLYSIS
of proinsulin, 726

SULFONYLUREAS
antilipolytic effects, *50
and diabetes mechanism, *407
and hypoglycemia, 522
and uricosuria, *593
-induced antabuse syndrome, 679-682
therapy, 503-507
and uremia, *170

SURGERY
amputation, 520-521
and gram-negative shock, *468
homografting, *715
hypophysectomy, *528
and hypophyseal stalk section, *318
and pancreatectomy, *300
ileal bypass
and hypercholesteremia, 208
and islet-cell tumors, *654
pituitary ablation, *294
pituitary cyroblation, 634-640
pituitary stalk section
and renal biopsies, *319-320
spinal cord section, *712
submaxillary salivary gland ablation, *325-326
thyroidectomy
and serum lipids, *777

SYNALBUMIN INSULIN ANTAGONISM
and idiopathic hypoglycemia of infancy, 557-559

T

TAURINE
urinary
and high sugar diet, *410

TAUROCHOLATE
and cholesterol synthesis, 75

TEMPERATURE
and glucose transfer in erythrocytes, *773
and insulin release, *298-299
and insulin storage, *311, 499-502
and plasma glucose and insulin levels, *335

TESTOSTERONE
and plasma free fatty acid, *114

TETRACYCLINE-14, 387

THEOPHYLLINE
and adipose tissue lipolysis, *341
and free fatty acid release, *329
and insulin secretion, *775-776

THORACIC DUCT
insulin, *174
lymph, *174

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

THYROID
and diabetes, *230
disease. *See* Hyperthyroidism and Hypothyroidism
function
and growth hormone secretion, 407
and pituitary cyroablation, 637-638
and starch and sugar
and serum lipids, *777
and sulfonylurea, 505-507

THYROTOXICOSIS
in Chinese diabetics, 228

TISSUES
adenosine 3′-5′-cyclic monophosphate, *528
adipose
and albumin, 380
and bacillus subtilis protease, *234
and control of cyclic 3′,5′-adenosine monophosphate metabolism, *711
and glucose I-C-14 metabolism, *334-335
and glucose-U-C-14 metabolism, *525
and glucose-6-phosphate dehydrogenase, *175
and growth hormone, *171
hexokinase, *300-301, *526-527
and hypoglycemia, *314-315, 489-491
and insulin action, *330
and insulin cleavage, *717
and insulin and glucose metabolism, *409
insulin and insulin-like activity, *53-54
and insulin response to protein, *297
insulin sensitivity, *656
and lipid synthesis, *51
lipolysis, *231, *233, *341, *411
lipolysis and glucose metabolism, *304
and proinsulin, *310
and protein synthesis, *173
adipose and diaphragm
and proinsulin, 737-745
adipose and kidney
and chlorothiazide-diazoxide, *592
brain
and glucose oxidation studies, 90-94
conjunctival
and microangiopathy, 391
epididymal adipose
and diet and weight, *528
gingival
and lipid distribution, *650-651
insulin catabolism in, *526
and insulin utilization, *591
pancreatic
and hexosemonophosphate shunt and hyperglycemia, *309
and insulin release, *343
rat ani muscle
and insulin, *229
rat diaphragm
glucose-fatty acid interactions in, 422-426
and insulin assay procedure, 369-370
and plasma albumin, 374-383
rat fat pad
insulin bioassay, *714-715

TOLBUTAMIDE
and acetohexamide comparison study, *469
and adrenalin, *350
and arterial disease, *328
and diabetes
and hypopituitarism, *654
and diabetic coma, 522
dosage
and metabolism study, *779
failure, *314
in human breast milk, *173
and hypoglycemia, *717-718
and insulin inhibition, 748-749, 750
and islet cell adenomata, 87, 88
and lipolysis, *50, *304-305
long-term therapy, 503-507
and serum response to glucose tolerance tests, *344
metabolism
and phenyramidol or bishydroxycoumarin, *175
and pancreas beta cells, *589
and pancreatic homografts, *715
and plasma insulin, 133-135
responses
and hypoglycemia, *113
and juvenile diabetes, *114
tests
and urine insulin output, *408

TOXEMIA
and diabetic pregnancies, *410

TRANYLCYPROMINE
and insulin secretion, 617-623

TRASYLOL, 179, 180, 182-185
and glucagon degradation, 189

TRIAMTERENE
and hyperglycemia, *528

TRIGLYCERIDES
and dietary fat, *111-112
and ethanol ingestion, *306
medium chain
and insulin secretion, *347-348
synthesis
and diabetes, *176

L-TRIIODOTHYRONINE
and renal gluconeogenesis, *348

TRINIDAD
diabetes survey in, *716

TRITIUM
incorporation
and fetal rats, 364-365

TRYPSIN, 437
and muscle permeability, *304
and proinsulin, 744

TUBERCULOSIS
in Chinese diabetics, 228

TUMORS
ACTH-producing
and endocrine adenomatose, 86
bronchial carcinoid
and insulin secretion, *471
Ehrlich ascites
and monosaccharides transport, *410
and potassium transport, *301-302
extrapancreatic
and hypoglycemia, *411
hypoglycemia, *233
and insulin secretion, 661-666
insuloma, *343
islet cell, 582-587, *654
mammosomatotropic
and islets of Langerhans, *308
mesenchymal
and hypoglycemia, *411

TURNER'S SYNDROME, *115
and growth hormone, *589, 672

TWINS
and diabetes, 693-703

TYROSINASE
and insulin oxidation, *112

U

ULCER
duodenal
and sulfonylurea, 505-507
leg, 227

UNITED KINGDOM
consumption of carbohydrates in, *114

UREA
formation
and insulin, *655
synthesis
and pyruvate, *411

UREMIA
and carbohydrate metabolism, *170
chronic
and potassium, *57

URETHAN
and adrenergic blocking agents, *54

URICOSURIA
and sulfonylureas, *593

URINE
acetoacetate
and Ketostix, 398-401
amino acids
of rats on high sugar diets, *410

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

copper, 269, 285
cortisol
radioassays, *655
diabetogenic polypeptide, *591
glycosuria
and retinopathy, *588
gonadotropins
and hypophysectomy, 637
immunoreactive insulin, *408
insulin 163-164
in newborns, *526
pantothenic acid
and diabetes, *292
proinsulin, *777
steroids
and diabetes, *407
testing accuracy, 281-285

V

VAGUS NERVE
stimulation
and gastric motility, *234
and insulin release, *308-309

VALINE
and insulin release, *171

VALINOMYCIN
and lipid membranes, *290
and potassium and sodium permeability of lipid membranes, *412

VALSALVA MANEUVER
and diabetic neuropathy, 273

VASCULAR DISEASE
in "borderline" diabetes, *328
and diabetes, *412
in diabetes survey, 223-224
femoral and popliteal occlusive, *326

VASCULAR SYSTEM
and insulin passage, 339, 668-671

VITAMINS
A
and eye lesions, 512
D
and protein synthesis, 218

VITILIGO, *712

VOCAL CORDS
paralysis, *302

VOMITING
and anorexia nervosa, 683
and gastric neuropathy, *412

W

WALLERIAN DEGENERATION EXPERIMENTS, 239-243

WEIGHT. *See also* Obesity
and ACTH and growth hormone, *290
and capillary fragility, *712
and carbohydrate and fat metabolism and serum insulin response, *591
change
and glycodiazine, 510
and chlorpropamide and metformin treatment compared, *524
in diabetes survey, 220, 222
gain
and diabetes, *412
and diabetic pregnancy, *410
and glucose tolerance, *409
and insulin response to glucose, *712
loss
and biguanides, 101
in maturity-onset diabetes, *325
and metabolism, *528
and phenformin hydrochloride, *711
and tumors, 661

WILD MONKEYS
arterial lesions in, 243, 260

WILSON'S DISEASE
and dietary copper, 269, 285

X

XANTHELASMA, 227

XANTHOMA
and clofibrate, *651

XYLITOL
and insulin secretion, *232

Y

YTTRIUM-90
implantation in pituitary gland, *294, 639

Z

ZOLLINGER-ELLISON SYNDROME, 299*

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

AUTHOR INDEX 1968

In this index are the names of authors of articles that have appeared in DIABETES and those whose articles have been abstracted in the Journal during 1968. Entries marked with an asterisk (*) indicate authors of material that appeared in the ABSTRACTS only. The Subject Index appears on page 1.

A

Abelove, William A., *314
Abrams, M. E., *412, *651
Abrams, Robert L., *314
Abramson, Eugene A., 141-146, *588
Aceto, Thomas Jr., *526
Ackerman, Eugene, *342
Adam, Peter A. J., *524
Adams, Andrew P., *326
Adams, Donald A., 634-640
Adams, Mildred, *234
Adesman, Jerome, *57
Adnitt, P. I., 628-633
Ahlquist, Raymond P., *176
Aho, Impi, *173
Ahrén, K., *229
Akerblom, Hans K., *308, *661-667
Akgun, Suat, *717
Aladjem, Silvio, *406
Albanese, Anthony A., *649
Albrink, M. J., *412
Alburn, Harvey E., 67-71
Alexander, D. Pauline, *588
Alexander, K., *290-291, *710
Allen, E. William, *56-57
Altszuler, Norman, 415-421
Amidi, Morteza, *171
Ammon, J., *294
Anderson, George E., *111
Anderson, J., *653
Andreoli, Thomas E., *290, *412
Andrew, Carole L., *654
Andrew, D., *592
Antar, M. A., *772
Antoniades, Harry N., *314, 427-436
Antonis, A., *111
Applebaum, Stephen, *349-350
Ariyan, Stephan, *468
Arky, Ronald A., 141-146, *306, *348 *588
Armaly, Mansour F., *50
Arquilla, Edward R., *329, *468, *649
Arsham, Gary M., *332-333
Asbury, Arthur K., *655-656
Ashcroft, S. J. H., *406, *710-711
Ashmore, James, *55
Ashworth, Murray A., *345-346
Avrill, A., *229
Axel, Carl, *470

B

Baars, J. D., *175
Babul, J., *113
Bach, H. G., *56
Bagdade, John D., *111-112, 127-132, *290, *315
Bahr, Albert L., *315
Bailey, Richard E., *319
Bain, Harry W., *231
Bak, Børge, *229
Baker, Lester, *170, *335, *406
Baker, P., *649
Balasse, E., *229, *290, *293-294, *588
Balcerzak, S. P., 468
Ball, Eric G., *113
Balodimos, Marios C., *303, *318, 503-508
Balogtou, Paul J., *50
Banker, Betty Q., *112
Barchuk, N. H., *53
Bar-Maor, Adoniram, *411
Barnardis, Lee L., *651-652
Barnett, D. M., *327
Barrett, Ronald A., *50
Barry, Kevin G., *318-319
Bass, Allan D., *320
Bassett, J. M., *711
Bates, Robert W., *290, 760-765
Battaglia, H., *316
Baukal, Albert, *350
Baum, David, *298-299
Baumslag, Naomi, *316
Bayliss, Claudia, *309, 725-736
Bean, W. B., *292
Beardwood, D. M., 17-26
Beaser, Samuel B., *332, *715
Bechmann, William H., 67-71
Beck, John C., *51, *334-335
Beck, Lyle V., *406, 444-457, *335
Beck, Paul, *307-308
Beigelman, Paul M., *173, *316, *528
Bellet, Samuel, *229, *324
Belts, Richard, *319
Bendersky, Gordon, *323
Benedetti, Andrea, 684-692
Benjamin, Fred, *112
Benmiloud, Moulai, *50
Bennett, Leslie L., *53, *468-469, *712
Bennett, P. H., *291
Berge, Kenneth G., 385-387
Berger, Sheldon, 72-75, *298, *593
Berkowitz, Donald, *317
Bernardis, Lee L., *301
Berne, Christian, *524
Berns, Aline W., *468
Bethge, Hartmut, *232
Bidone, Giovanni, 133-135
Bieberdorf, Fred A., *317
Bierman, Edwin L., *111-112, 127-132, *290, *315, *649
Bilder, Joan H., *321
Billaud, L., *591
Birk, Sharon A., *592
Birkbeck, J. A., *317-318
Bischoff, A., *468
Bjerknes, Clara, 415-421
Blackard, William G., *471
Blackwell, W. L., *407-408
Blattner, Russell J., *772
Blecher, Melvin, *711
Bleicher, Sheldon J., *57, *304, *592-593
Blickens, D. A., 646-647
Bliffen, G., *412
Blizzard, Robert M., *173-174, *716-717
Block, Melvin A., 520-521
Blom, P. S., *175
Blumenthal, Stanley A., *229-230
Boden, Guenther, *318, *406
Bodenbender, Joann G., *774
Bodin, F., *712
Bojanowicz, Kazimierz, *230
Bolinger, Robert E., 61-66
Bongiovanni, Alfred M., *115
Bookman, John J., *320
Born, James L., *113, *318
Bortz, Walter M., 90-95
Boshart, C. R., 646-647
Boshell, Buris R., *54-55
Bowen, Angela J., *50
Bower, B. D., *406-407
Bowers, Cyril Y., *588
Bradbury, James T., *469
Bradley, Robert F., *318, *338
Braithwaite, Fenton, *116
Brancato, Paul, *176, *306-307
Brandt, E. N., *114
Brånemark, P.-I, *230
Brauman, H., *407
Braunsteiner, H., *649

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

Brech, W. J., *772, *777
Breitbach, A., *588
Brennan, Mildred L., *56-57
Brenner, Rodolfo R., *711
Bressler, Rubin, 617-624, 679-683
Bricaire, H., *776-777
Brice, Larry, *319
Brinkmann, W., *717-718
Britton, H. G., *588
Brodoff, Bernard N., *112, *655
Brolin, Sven E., *524
Bromer, William W., *468
Brooks, Marion H., *318-319
Brosky, Gerald, *306
Brown, Charles H., *717
Brown, G. A., *116
Brown, H., 673-678
Brown, Joseph D., *50, *304-305
Brown, Josiah, *526-527, *649-650
Brown, Thomas O., *176
Browning, Edward T., 194-208
Brunet, Gunther, *411
Brunfeldt, K., *650
Brush, James S., 369-373
Bucalossi, A., 124-126
Buchanan, Keith D., 179-186, 187-193, *299, *311-312, *468
Buhi, W. C., *344-345
Burch, G. E., *170
Burch, T. A., *291
Burday, S. Zane, *772
Burditt, Anne F., 121-123, *588
Burger, H. G., *233
Burgess, John A., *114-115
Burns, Rachel, 281-285
Burstein, Josef, *711
Burton, Stanley D., *336
Busch, Dovre H., *332
Buse, Maria G., *54
Butterfield, W. J. H., *412, *651, *779
Byrne, John J., 437-443

C

Cahill, George F., Jr., *174, *326, 362-368
Caird, F. I., 121-123, *588
Camerini-Dávalos, Rafael A., *301, *346-347
Campbell, James, *112
Caradang, N., *319
Carlson, Karen L., *412, *592
Carlson, Lars A., *230, 353-361
Carpenter, Frederick H., 526
Casper, Donald J., *112
Castro, Albert, *319
Castro, Oscar De, *324
Catt, K. J., *233
Caulfield, James B., *319-320
Cavicchi, Phyllis, *58
Cerasi, Erol, *293, *470
Ceresa, F., 570-578
Cerichio, Gerard M., *314
Challoner, David R., 187-193
Chambers, John, *320
Chance, Ronald E., *310, 737-745
Chang, Catherine, *349
Chao, Kuen-Lan, 27-32, *593
Charro-Salgado, A. L., *407
Chazan, Bernard I., *303
Chen, Robert, 179-186
Cheraskin, Emanuel, *50
Cherry, Sheldon H., *320
Chester, Edward M., *112
Chiles, Ross, *343
Chiumello, Giuseppe, 133-135, *320-321
Chlouverakis, C., *230
Cho, Sooja, *309, 725-736, *777
Choi, Young, 509-512
Chong, Claude Y., *318
Chowdhury, Faizur R., *304
Christensen, Niels J., *650
Chu, Ping Chi, *407, *650
Ciric, Ivan S., *232
Cirillo, R., 489-491
Clark, Charles M., *300, *317, 362-368
Clark, Dale A., *231
Clark, J., *309-310
Clark, John W., *716
Clark, M. L., *111
Clarke, B.F., *407, 458-467, *524
Claycomb, William C., *329
Clements, Rex S., Jr., *299-300
Cleve, H., *290-291
Cloutier, Roger J., *408
Coërs, C., *590
Cogan, David G., *170
Cohen, Bernard, *322
Cohen, Burton D., *170
Cohen, H., *712
Cohen, Nicholas M., *233, *588, *653-654
Cohn, Clarence, 72-75
Cole, Harold S., *321
Coll-Garcia, E., *710-711
Collins, W. E., *321
Colwell, Arthur R., Sr., 599-610
Colwell, John A., 83-89
Conn, Jerome W., *171, *297, *524-525, *591
Connor, Thomas B., *716
Conrad, V., *293-294
Conte, M., *712
Conte-Marti, J., *712
Contini, P., 124-126
Conway, Martin J., *650
Cook, P., *412
Copinschi, Georges, *50
Cornblath, Marvin, 27-32, *173, *593, *717
Cornog, John L., Jr., *650-651
Cortazar, Jaime, *341
Corvilan, J., *407
Cory, Joseph G., *112
Couturier, E., *229
Crane, C. W., 625-627
Cremer, Guillermo M., *342
Crespin, Stephen R., *409
Crockford, Peter M., 179-186, *297, *340
Crofford, O. B., *303-304
Crome, L., *230
Csorba, T. R., *651
Cullen, J. F., 458-467
Culp, Hilman W., *170
Curry, Donald L., *468-469
Czyzyk, Arthur, 492-498

D

Dakshinamurti, K., *772
Daliqcon, Bonifacio C., *115
Danforth, Elliot, Jr., *318-319
Danho, W., *656
Daniels, Jerl P., *775
Danowski, Thaddeus S., *112, *171
Darle, N., *54
Dashe, Alfred M., 634-640
Daunnas, J., *655
Davidoff, Frank F., *407
Davidson, I. W. F., *407-408
Davidson, John K., 8-12, *345-346
Davidson, Mayer B., *312
Davis, Walter T., *173-174, *716-717
Dawber, Rodney P. R., *712
Daweke, H., *591
Debons, Albert F., *408
DeChatelet, Lawrence R., *588
Deckert, Torsten, *651
Del Guercio, Maria Jose, 133-135
Del Rio, Alejandro, *717
Denton, R. M., *50-51
Dérot, M., *776-777
Derron, R., *590
Devrim, Sevim, *330, 746-751
Dhurandhar, Nina R., *471
Dieterle, P., *112
Dignam, William J., *291
Dill, I. K., *234
Dimick, M. K., *114
DiPlacido, John, *54
Di Raimondo, Vincent C., 147-151
Ditzel, Jorn, 388-397
Dobson, Harold L., 281-285
Doeblin, Thomas D., *324
Doffing, Kenneth M., 61-66
Doisy, Richard J., *410-411
Dolger, Henry, *320
Donaldson, Charles L., *344, *589
Donnell, George N., *654
Dorn, Janice, *112
Douglas, L. I., *321
Dovetall, G., *54
Downey, Dorothea, *341
Draper, G. J., 121-123, *588
Drash, Allan, *652
Drenick, Ernst J., *57
Driscoll, Shirley G., *51
Dtizov, S., *592
Duncan, Garfield G., *469, *651
Duncan, L. J. P., *407, 458-467, *524
Duncan, R., *114
Duncan, Theodore G., *469, *651
Dunn, A., *54

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

Dunn, Leo J., *469
Dürr, F., *774

E

Earil, Jerry M., 147-151
Eash, Sandra A., *55
Eaton, S. Boyd, *772-773
Ebbin, Allan J., *170-171
Eberlein, Walter R., *115
Echenique, Raul, *314
Eckhardt, Richard D., *340
Edelberg, Stuart, *320
Edwards, J. R. G., *116
Egdahl, R. H., *339, 668-672
Egleston, Thomas A., *717
Ehrenreich, Theodore, *301
Ehrlich, Robert M., *113, *231
Eisentraut, Anna, *312, *321-322
Elcombe, A. M., *174
Ellenberg, Max, *322, *773
Ellerman, J. E., *309, 475-480
Elliott, Frank A., *651
Ellis, Julia P., *175
Emerling, Frank G., *324
England, J. D., *326, *336-337
Ensinck, John W., *53-54, *116, *313, *347, *716
Erdohazi, Magda, *230
Erlandsen, Stanley L., *322-323, *651
Ernesti, M., *336
Ertel, Norman H., *592-593
Esterhuizen, A. C., 33-36
Estrich, David L., *323
Evans, T. C., *292
Everson, Gladys J., *589, *718
Ezdinli, Ediz Z., *712

F

Fagerberg, S.-E., *230
Faiman, C., *408
Fajans, Stefan S., *171, *297, *524-525
Falkmer, Sture, *231, *773
Faludi, Georgina, *323
Farquhar, John W., *174, *323-324
Farrant, P. C., *712
Fatourechi, Vahab, *342
Fedynskyi, Nathalie, *406
Feinberg, Leonard J., *324
Fenichel, Richard L., 67-71
Fenster, L. Frederick, *116
Fernandes, J., *589
Fessler, Alfred, *51
Field, James B., *294, *328
Field, Richard A., *319-320
Fillson, Edgar J., *717
Findlay, J. A., *589
Fine, Paul H., *772
Finster, Joseph L., *527
Fisher, Edwin R., *171
Fitts, William T., Jr., *650-651
FitzGerald, M. G., 398-401
Fleischli, Donald J., *772-773
Flores, Placido, *524
Floyd, John C., Jr., *171, *297, *524-525
Flury, R., *233
Foa, Piero P., *343, 582-587
Folk, Robert L., *653
Fono, P., *348-349
Forbes, Audrey E., *173
Forsham, Peter H., *50, *176, *332, *344, *471, *589, 684-692
Forsling, Mary L., *651, *773
Forssman, Wolf G., *293
Förster, Harald, *232, *293
Fortney, Sidney R., *231
Franckson, J. R. M., *229
Frankhauser, S., *471
Franklin, Sidney N., *408
Fraiser, S. Douglas, *171, *525, *654
Fredrickson, Donald S., *51-53
Freinkel, Norbert, *50, *312, 437-443, *469
Freund, Gerhard, *291
Freyschuss, Ulla, *230
Frieden, Earl, *112
Friedman, Sandor A., *113
Friedmann, Bernice, *231, *408
Fritz, Irving B., 194-208
Froesch, E. Rudolf, *231-232, *233, *411
Frohman, Lawrence A., *232, *526, *301, *324, *651-652
From, Annette, *408
Frumusan, P., *712
Fujimura, Akira, 286-289
Fukayama, George, *323
Furey, Warren L., 83-89
Furuta, F., *114

G

Gabbay, Kenneth H., 239-243, *300
Gaffney, Thomas E., *292-293
Gagliardino, Juan Jose, *408
Gall, S. A., *412
Galloway, John A., *170
Garay, Gabriel, 661-667
Garces, Ludivian, *652
Garcia, Joseph F., *113
Garcia, Luis A., *717
Garcia, M. J., 17-26
Garratt, C. J., *412
Garrison, Mary N., *290
Gattner, Hans-Gregor, *718
Geiger, J. W., *55
Genuth, Saul M., *291, *324-325
Gershberg, Herbert, *325, *327, *409, *590
Geser, K. A., *232
Ghemi, F., 570-578
Ghidoni, A., *411-412
Gill, J. R., *589, *710-711
Ginos, James, *410
Ginsberg-Fellner, Fredda, 261-269
Gjedde, F., *652
Gleason, Ray E., 17-26, *298, *339, *344, *350, 503-508, 752-759
Glennon, J. A., *777
Glick, Gerald, *776
Gliemann, Jørgen, *408-409, *655
Godlowski, Z., *325-326
Goetz, Frederick C., *343, *471, *774
Gold, Hugo, *525
Goldberg, A. M., *308-309
Goldberg, M.D., *328-329
Goldberg, Morris, *57
Goldman, Jack K., *301
Goldmann, J., *55
Goldner, Martin G., *57, *345
Goldrick, R. B., *409
Goldsmith, Lowell, 766-771
Goldstein, Samuel, *326
Goldziehr, J. W., *344-345
Goñi, P. M., 55
Gonzalez, C., *113
Goodman, A. David, *173, *778
Goodman, Edward H., Jr., *231, *408
Goodman, H. Maurice, *171
Goodner, Charles J., *407, *650
Goodridge, Alan G., *113, *525
Gorden, Phillip, *310
Gordon, Edwin E., *301-302
Gordon, E. S., *777
Gorman, C. K., *232
Goto, Yoshio, *470
Gottlieb, Marise S., 693-704
Graber, Alan L., *314
Graff, Edward S., *525
Graff, G., *590
Gramm, Herbert F., *412
Grande, Francisco, *342-343, *777
Grant, Alison, *528
Grant, D. B., *232, *589
Grasso, Sebastiano G., *176, *306
Graves, Thomas M., *347-348
Graves, William K., *291
Greaves, J. P., *114
Green, Paul A., 385-387
Greenberg, E., *294, *528
Greenberger, Norton J., *347-348
Greenough, William B., *409
Greenslade, K., *526-527
Greenwood, F. C., *175, *409, *653, *773-774
Gries, F. Arnold, *232, *591
Grillo, T. Adesanya Ige, 582-587
Grodsky, Gerold M., *53, *176, *468-469, 684-692, *712
Gross, Richard C., 353-361
Grüneklee, D., *591, *775
Gubernick, I., *316
Guggenheim, Wolf, *326
Guha, Atin, *318
Guntsche, Enrique M., *171, *524-525
Guthrie, Richard A., *291, *326, *336-337
Gutman, Alexander B., *593
Gutte, Bernd, *718

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

H

Hackel, Donald B., *232
Hackeng, W. H. L., *116
Hadden, D. R., *171-172
Haft, David E., 244-250, 251-255
Hagemann, R. F., *292
Haist, R. E., 8-12
Hajdu, A., *291
Halasz, Nicholas A., *468
Hales, C. N., *409, *713, *773-774
Hall, Luther, *318
Halling, George R., *53
Hallund, Ole, *309, 725-736
Halter, Jeffrey B., *774
Hamberger, Carl Axel, *470
Hambidge, K. Michael, 517-519
Hamburger, J., *776-777
Hampers, Constantine L., *174
Hamwi, George J., *58, *174, *292, *653
Hane, Satoshi, *50, *344
Hanley, John, 634-640
Hansen, B. A., *650
Hansen, Robert J., *300-301, *409
Hardin, Harry, *349-350
Hardy, Jules, *232
Harris, B., 522
Hart, A., *712
Hart, J. C. D., *232
Harth, Albert, *652
Hatano, M., *292
Hausinger, A., *115-116
Hawley, William D., *588
Haworth, J. C., *53
Hayduck, K., *774
Hazeltine, Frederick G., *113
Hazlewood, Carlton F., *589
Hazelwood, Robert L., *589-590
Hazzard, William R., 179-186, *297
Heath, H., *232
Hecht, Arthur, *409
Heimberg, Murray, *176
Heinrichs, R. W., *302
Hellerström, Claes, *53, *713
Hellman, Bo, *53, *233, *409
Henderson, J. R., *652-653
Hennes, Allen R., *116
Henriques, Kathleen J., *170
Henry, Harry J., *311, 499-502
Henry, M. V., *716
Hensley, George T., *653
Hepp, Dieter K., *53-54, *116, *330, *716
Herberg, L., *775
Herbst, M., *649
Herr, F., *291
Herrera, Fernando, *234
Herrera, M. Guillermo, *339, 668-672, *717
Herron, Arthur L., Jr., *56-57
Hertelendy, F., *527, *653
Hetenyi, G., Jr., *713
Heuser, Gunnar, 634-640
Hildebrand, J., *590
Hildebrandt, H. E., *294
Hill, D. M., *653
Hirsch, Jules, *656
Hivet, M., *712
Hoar, Carl S., *326
Hodge, R. L., *111
Hodges, R. E., *292
Hohl, R. D., *327
Hollander, Daniel, *299
Hollingsworth, Dorothy F., *114
Hollobaugh, Samuel L., *292, *653
Holmlund, C. E., *234
Holzbauer, Margarethe, *469
Holzel, A., *233
Horger, E. O., III, *409-410
Horino, M., *527, *653
Horton, Edward S., *233
Howell, S. L., *313, *713
Huang, K. C., *469
Huff, Thomas A., *233
Huijing, F., *589
Hulse, Mildred, *325, *590
Humbel, R. E., *590, *774
Hung, Wellington, *410
Hunter, Stewart, *469-470
Hunter, W. M., *175, *713-714
Huntley, Carolyn, *170-171
Hurwitz, David, *341-342
Huseby, Robert A., *327

I

Ibayashi, Hiroshi, *173
Ipp, E., *303
Ireland, J. T., 458-467
Irvine, G., *589
Ishiwata, K., *713

J

Jackson, R. L., *326, *336-337
Jackson, Ruth M., *334
Jackson, W. P. U., *328-329, *348, *590, *779
Jacobs, Murray, *318
Jacobson, Mitchell, *297
Jahnke, K., *591
Jakob, A., *233
Jakobson, Theodor, *711, *714
James, V. H. T., *653
Jangaard, N. O., 96-104
Jaqua, Richard A., *319-320
Jarrett, R. J., *233, *328, *470, *653-654, *714, *774, *778-779
Javid, Rouliah, *712
Javier, Zenaida, *590
Jenkins, David J. A., *54
Jensen, V. A., *590
Jimenez, Jose A., *337
Joffroy, A., *590
Johansen, Klaus, *114
Johanson, A., *716
Johansson, Sören, *292
Johnson, H. Keith, *654
Johnson, Stanley, *292, *410
Jonsson, Anders, *305
Jørgensen, K. R., *650
Joven, Claricia B., *57
Jurgensen, Craig, 520-521

K

Kaess, H., *772
Kahanpaa, Asko, *714
Kahil, M. E., 673-678
Kahn, C. B., *298, *344
Kalkhoff, R. K., 34-47, *307
Kallio, I. V. I., *172
Kanazawa, Yasunori, *173
Kaneto, Akio, *172
Kansal, Prakash, C., *54
Karam, John H., *176, 684-692
Karl, Irene E., 374-384
Kasemir, H., *714
Kassoff, Aaron, *173
Katsoyannis, Panayotis G., *54, *292, *410
Katz, Alma, *349-350
Katz, J., *54
Kauffman, F. C., *309, 475-480
Kaufman, Barry J., *327-328
Kaye, Robert, *170, *335, *406
Keen, H., *328, *470, *774, *778-779
Keller, P., *328-329, *779
Kellett, W. W., III, *409-410
Kelley, W. N., *470
Kemp, Donald R., *234
Kenny, Frederick M., *652
Kent, Gerald T., 274-280
Kerp, L., *714
Kew, M. C., *303
Khalouf, Shirley Thompson, *114
Kieling, F., *714
Killian, Paul, *312
Kilo, Charles, 746-751
Kilsheimer, Grace S., *329
Kim, H., *307
Kimberling, William, *319
King, Katherine, *524
Kinney, J. M., *55
Kinsell, Laurance W., *306, *323
Kipnis, David M., 27-32, 422-426, *527-528, *593, *653
Kirtley, William R., *311
Kitabchi, Abbas E., *299, *470
Kjelberg, Jan, *230
Klimas, John E., *654
Klitgaard, Howard M., 369-373
Klomberg, G. H., *777
Klonoff, H., *317-318
Knapp, M. S., 522
Knight, G. J., *653
Knittle, Jerome L., *656
Knopf, Ralph F., *171, *297, *524
Knowles, Harvey C., Jr., *590-591
Koch, B., *321
Koch, Gert, *326
Kochwa, Shaul, *320
Kock, N. G., *54
Kogut, Maurice D., *525, *654
Koh, C. S., *233
Kohn, J., *233

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

Kolber, Alan R., *410
Kolodny, Howard D., *525
Kologlu, Yusuf, *111
Komatsu, K., *114
Konikova, S. A., *591
Kontras, Stella B., *774
Koons, Dexter, *714
Kosaka, Kinori, *172
Koszalka, Thomas R., *654
Kozak, George P., *412
Krahl, M. E., *300-301, *409
Krehl, W. A., *292
Kreines, Kenneth, 509-512
Kreisberg, Robert A., *54-55, 194-208, 481-488
Krimsky, Isidore, *408
Kritzman, M. G., *591
Krouse, Howard A., *650
Kruger, Fred A., *292
Kuksis, A., *348-349
Kuo, J. F., *234
Kuo, Peter T., *650-651
Kuttner, Robert E., *410
Kuwabara, Toichiro, *170, *303, 503-508
Kuzuya, Takeshi, *173

L

Labhart, A., *233
Lacey, A. H., 705-707
Lacey, Paul E., *313, *774-775
Lai, G., *329-330
Laidig, Ruth B., *332-333
Lakshmanan, Florence L., *234
Landing, Benjamin H., *525
Landon, J., *653
Lange, Kurt, *301
Langer, L., *230
LaNoue, Kathryn F., *775
Laron, Z., *55
Lauris, Vilma, 611-616
Lavender, A. R., *173
Lavis, Victor R., *330
Lawrence, John H., *113, *318
Lazarow, Arnold, *651
Lazarus, Norman R., *330
Lazarus, Sidney S., 152-160, *176, *306, *330-331
Lea, Michael A., *527
Lebovitz, Harold E., *232, *233, *292, 617-624
Lecks, Leonard E., *324
Leeper, D. B., *292
Lees, Robert S., *51-53
Lefebvre, Pierre J., 582-587
LeFevre, Paul G., *410
Legg, Merle A., 503-508
Lein, Allen, *778
Lemberg, A., *655
Lemen, J., *651
Lenti, G., 489-491
Leonards, Jack R., 274-280
Lepkovsky, S., *114
Lerner, Roger L., *174
Lestradet, H., *591
Lever, J. D., 33-36, *589
Levine, Rachmiel, *301, *325-326, *525-526, *655
Levine, Robert A., *410-411, *470
Levy, Daniel, *526
Levy, Leonard, *345
Levy, Robert I., *51-53
Lieber, Arthur, *172, *334
Liebermeister, H., *591, *775
Light, Irwin J., *292-*293
Like, Arthur A., 752-759
Likuski, Henry J., *408
Lillenstein, Mark, *303
Lin, B., *348-349
Lindell, Kurt A., *711
Linfoot, John A., *113, *318
Ling, Shun M., *654
Linzell, J. L., *114
Littlefield, John W., *326
Lloyd, J. K., *777
Loeffler, Robert W., *331
Loggie, Jennifer, M., *292-*293
Logothetopoulos, John, *306
Long, C. L., *55
Longmire, William P., Jr., *654
Lopez-Quijada, C., *55
Lopis, S., *655
Lorenze, Edward J., *649
Lorincz, Albert B., *410
Louis, L. H., *591
Lowenstein, B. E., *316, *331
Lowy, Clara, *175, *526
Lucchesi, Benedict R., *775
Luft, Rolf, *293, *470
Lundbæk, Knud, *114, *294, *590
Lundquist, Ingmar, *526, *714-715
Luntz, George R. W. N., 625-627
Lyman, John, *318
Lynn, T. N., *114

M

Macchi, I. A., *332, *715
Macdonald, I., *715
MacGillivary, Margaret H., *526
Machlin, L. J., *527, *653
Mack, E., *339, *668-672
Mackay, Ian R., *175-176
Mackenzie, Malcolm S., *332-333
Maclaren, Mary, *331-332
MacMillan, Duncan R., *55
Madison, Leonard L., *305, *715
Mager, Milton, *312, *469
Mahan, Clare M., *337, *716
Mahler, Richard J., 1-7, *333
Maier, Jacqueline J., *346-347
Makulu, David R., 513-516, 537-546
Malaisse, Willy J., *55, *58, *234, *308, *527, 537-546, *718, 752-759, *775-776
Malaisse-Lagae, Francine, *55, *234, *308, *527, 752-759, *775-776
Manchester, K. L., *172
Mandelbaum, Isidore, *333-334
Mandelstam, Paul, *172, *334
Manderson, W. G., 13-16
Mangurten, Henry H., *717
Manners, D. J., 13-16
Mannheimer, S., *55
Manougian, Edward, *113, *318
Manford, K. R. L., *592
Marble, Alexander, 17-26, *298, *339, 503-508
Marcus, Daniel F., *715
Margolin, Morris, *334
Marine, N., *328, *590, *779
Mark, Peter, *291
Marks, Vincent, *172-173
Martin, Donald B., *305
Martin, F. I. R., *175-176, *715-716
Martin, Julio M., *113, *308, 661-667
Martin, Luis G., *716
Martini, P. F., 570-578
Martino, P., 570-578
Maruhama, Yoshiuke, *470
Mascia, V., 489-491
Mason, Arthur D., Jr., *775
Mason, George, *593
Massey, Frank J., *57
Matschinsky, F. M., *309, 475-480
Matsuda, Tamotsu, 286-289
Matz, Robert, 108-109, *172
Mayhew, D. A., *234, *308-309
Mayne, N., 270-273
McCoy, J., *412
McDonald, Hugh J., *588
McFadzean, A. J. S., 219-228
McGavran, Malcolm H., *327
McKay, Eric, *469-470
McKendry, J. B. R., *321, *331-332
McKiddie, M. T., 13-16, *468
McKusick, Victor A., *114-115
McLean, J. M., *294, *528
McLean, Patricia, *526-527
McMahon, Robert E., *170
McMillan, Donald E., *332, *471
McNeish, Alexander S., *776
McTaggart, A. H., *317-318
Meade, Robert C., 369-373
Meek , Joseph C., 61-66
Megyesi, Clara, *172-173
Mehnert, Hellmut, *232, *293
Mehtalia, Suresh D., *337
Meissner, H., *775
Mellati, A. M., *334-335
Menachem, Nitzan, 579-581
Merchant, James A., *469
Mercola, Karen, *329-330, *649
Mercuri, Osvaldo, *711
Mereu, Tullio R., *173
Merimee, Thomas J., *114-115, *347, *655
Merlino, Nancie S., *711
Metz, Robert, *298, *411, *776
Meyer, U. A., *233, *411
Michaels, Edward L., *53
Miettinen, Tatu A., 76-82, 209-218
Migeon, Claude J., *410, *716-717
Mikat, E., *232
Miller, Daniel, *589
Miller, K., *777

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

Miller, Leona V., *173
Miller, M., *291
Miller, Max, *332-333
Miller, Michael E., *170, *335
Miller, Robert W., *335
Miller, Rupert, 560-569
Milner, R. D. G., *713
Minemura, T., *303-304
Mintz, Daniel H., *468, *527
Missmahl, H. P., *592
Mistry, S. P., *772
Mitchell, F. L., *407, *409, *411, *773-774
Mitchell, M. L., *336
Mitzkat, H. J., *290-291, *710
Miyabo, Susumu, 286-289
Model, Peter, *115
Modi, V. V., *772
Mohammed, Mary F. B., *332-333
Moiel, Richard H., *173
Molnar, George D., *342
Molony, Margaret, *111
Mondon, Carl E., *336
Moody, A. J., *655
Moorhouse, John A., *302, *327-328, *408
Moosnick, Franklin B., *334
Morenkova, S. A., *591
Morgan, Carl R., *333-334
Moses, Doris, *779
Moses, L. C., *344-345
Mottram, R. F., *649
Moxness, Karen E., *342
Munro-Faure, A. D., *653
Munsie, William J., *592
Murakami, Mototaka, 286-289
Murphy, Beverley E. P., *655
Murthy, D. Y. N., *291, *326, *337-338

N

Nabarro, J. D. N., *175
Nagano, Toshio, 582-587
Nakanishi, Richard, *174
Nakao, Kiku, *172, *173
Nancie, S., *711
Narahara, H. T., *304
Narita, N., *114
Naughton, J. P., *114
Nebesar, Robert A., *772-773
Nechemias, Charles, *320
Neff, Robert, *291
Nelson, George H., *176
Nelson, J. K., *655
Nestel, P. J., *234
Neumann, P., *590
Neville, R. W. J., *712
Newport, Helen M., *469
Nielsen, Aa. V., *655
Niemeyer, H., *113
Nigam, A., *316
Nikiforow, Rita E., *711
Nikkila, Esko A., 76-82, 209-218
Nissan, Shemuel, *411
Nissen, P., *290-291
Nitzan, M., *55
Nixon, D. A., *588
Noble, Adele, *234
Nolan, J., 458-467
Norton, Margaret, 72-75
Nusynowitz, Martin L., *55-56

O

O'Brien, Donough, 517-519, *592
Ohneda, Akira, *312, *321-322
Ohsawa, Nakaaki, *173
Oliver, M. F., 458-467
Oller, D., *337-338
Olsen, Karl J., *114
O'Meallie, L. P., *170
Ooms, H. A., *293-294, *588
Ooms, Henri, *649
Openshaw, Harry, 90-95
Opie, Lionel, *592
Oppenheim, Abraham, *229
Opperman, Werner, *301, *337
Orci, Lelio, *293
Orskov, Hans, *650
Orto, Louise A., *649
Oscancova, K., *56
Östman, Jan, *230
O'Sullivan, John B., 239-243, *300, *337, *716
Owen, John A., Jr., *592
Owens, Guy, *712
Oyama, Jiro, *115

P

Paddu, Paolo, *57
Pagano, G., 489-491
Pao-Lo Yu, 537-546
Papadopoulous, Constantin, *111
Parada, Eugenio, *312, *321-322
Park, R., *114
Parker, Mary L., 27-32, 634-640
Parker, R. A., *588
Parmley, William W., *776
Parra, Adalberto, *342
Parrish, A. E., *337-338
Partamian, Jean O., *338
Passmore, R., *175
Paterson, R. A., *232
Path, M. C., 105-107, 625-627
Patrick, R. S., 105-107
Pattee, C. J., *528
Paulsen, C. Alvin, *53
Paulsen, Elsa P., 261-269
Pazianos, A. G., *294, *528
Pearson, J., *411
Pearson, M. J., *715-716
Pearson, Olof H., *525
Pedersen, Erik Jonas, *229
Pek, Sumer, *297
Pelkonen, Risto, 76-82, 209-218
Pellegrini, A., 489-491
Peluffo, Raúl O., *711
Penchev, I., *592
Penhos, Juan C., 1-7, *232, *338, *350, *655
Péquignot, H., *776-777
Pereira, J. N., 96-104
Peretz, W. L., *294, *528
Perez-Stable, Eliseo, *171
Perley, Michael J., *527-528
Perova, N. V., *591
Persson, B., *56
Petti, Mario, *525
Pfeiffer, E. F., *294, *592
Picard, C., *293-294
Picon, L., *411
Pictet, Raymond, *293
Pi-Sunyer, Xavier, 437-443
Pildes, Rosita S., 27-32, *173
Pilkington, T. R. E., 111
Pilkis, Simon J., *300-301, *409
Pinson, Rex, 96-104
Pinter, E. J., *528
Piver, M. Steven, *294
Podgainy, Helen, 679-683
Podolsky, Stephen, 766-771
Poffenbarger, Philip L., *53-54, *116, *716
Pollard, James J., *772-773
Ponikowska, Irena, 492-498
Pooler, Karen, *292
Poon-King, T., *716
Poppius, Hakan, 209-218
Porte, Daniel, Jr., *111-112, 127-132, *290, *298-299, *315, *338-339, *649
Portoghese, Andrew, *410
Posey, Iva J., 513-516
Posner, Barry I., 427-436
Potsaid, Majic S., *772-773
Power, Lawrence, *116
Pozza, G., *411-412
Prasad, A. L. N., *170
Prasannan, K. G., *471
Probst, G., *591
Prockop, Leon D., *299-300
Pröls, H., *232
Pullman, Theodore N., *173
Pupo, Armando, *338-339

R

Rabajille, E., *113
Raben, M. S., *336
Rabinowitz, David, *114-115, *347, *655
Raff, Martin C., *655-656
Raiti, Salvatore, *173-174, *716-717
Ramos, E., *339
Rampersad, F., *716
Rand, Robert W., 634-640
Randle, P. J., *50-51, *406, *589, *710-711
Raptis, S., *592
Rasio, Eugenio A., *174, *339, 668-672
Rastogi, Krishna Sudha, *112
Rathgeb, Isbel, 415-421

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

Ray, B. S., *294, *528
Rayner, P. H. W., *406-407
Read, Charles H., *55
Reaven, Gerald M., *174, *323-324, 560-569
Recant, Lillian, *330, 374-384, 746-751
Rees, Searle B., *318
Reeves, Robert L., *50
Reinheimer, W., *412
Remfry, Jennifer C., *651
Renner, Ruth, *174
Rennick, Phillip, *349-350
Renold, Albert E., *293
Renschler, H. E., *56
Rerup, Claus, *526
Reske-Nielsen, Edith, *294
Restelli, Mario A., *711
Reynolds, Ian J., *58
Richards, Nelson G., *714
Richardson, B. L., 34-47
Richenderfer, Lee, 261-269
Riemann, J., *592
Riggi, S. J., 646-647
Riggs, Lamar, *114-115
Rimoin, David L., *114-115, *776
Ringsdorf, W. Marshall, Jr., *50
Rippey, John H., 503-508
Rittenberg, David, *115
Rivers, R. P. A., *230
Ro'Ane, Jacquelynn T., *711
Roberts, Nancy M., 537-546
Roberts, Stuart S., *717
Robertson, Patrick D., *339-340
Rodbell, Martin, *174
Roddam, Roy F., *54
Rodgerson, Denis O., 517-519
Rodriguez-Antunez, Antonio, *717
Rohs, M., *772
Rojas, L., *344
Roman, Laurian, *229
Romney, S. L., *115-116
Rona, G., *291
Root, Allen W., *115, *170, *406
Root, Howard F., 693-704
Root, Mary A., *170
Rosenbloom, Arlan L., 557-559
Rosenbloom, F. M., *470
Rosenfeld, Robert L., *115
Rosenfield, Richard E., *320
Rosevear, John W., *342
Rosselin, G., *776-777
Roth, Jesse, *310
Roth, Nathan H., 634-640
Rouiller, Charles, *293
Roux, J. F., *115-116
Roy, Claude C., *592
Rubenstein, Arthur H., 161-169, *655, 725-736, *777
Rubinstein, David, *51, *334-335
Ruderman, Neil B., 611-616, *717
Rudman, Daniel, *717
Rüenauver, R., *775
Rull, Juan A., *171
Rutherford, Anne, *175
Ryan, Jerome R., *173
Ryan, Joseph, *343

S

Saarimaa, H. A., *172
Sadowski, Jan, 492-498
Saiki, John H., *776
Sailer, S., *649
Salans, Lester B., *656
Salinas, Ezequiel D., Jr., *717
Salsberg, Barry B., *340
Salter, James M., *232, *411
Salzmann, I., *290
Samaan, Naguib, *340, *525
Samols, Ellis, *172-173
Samson, R. I., *56
Sanbar, Shafeek S., *717
Sanchez-Median, Mario, *341
Sandberg, Herschel, *324
Sanders, Paul, *346
Sandhofer, F., *649
Sangalang, Virgilio, *655-656
Saporito, N., *306
Sargent, Joseph, *349-350
Sarver, Margaret E., *171
Sauer, Jean H., *305, *471
Saunders, S. J., *56
Save-Söderbergh, J., *230
Schade, Sandra L., *592
Schalch, Don S., *315, *772
Schatanoff, Joseph, *651
Schedl, Harold P., *524
Schein, Philip S., 760-765
Schiff, D., *526
Schilling, W. H., *591, *775
Schlierf, G., *772
Schlosser, Gerald, *316
Schmid, Florence G., *53
Schmid, Julie M., *55
Schmidt, G., *656
Schmidt-Nielson, K., *232
Schnatz, J. David, *301, *341
Schofield, J. G., *174
Schollmeyer, P., *774
Scholz, Roland, 194-208
Schonfeld, Gustav, 422-426
Schopman, W., *116
Schreibman, Paul H., *341-342
Schrogie, John J., *175
Schultz, Alvin L., *342-343, *777
Schultz, Robert B., *342
Schulz, E., *717-718
Schuman, B. M., *319
Schuster, Ernest M., *234
Schwartz, Gerald, *410
Schwartz, Marshall Z., *774
Schwartz, Robert, *524
Schwarz, H., *294
Scott, James, *319
Scott, Robert B., *718
Scow, Robert O., *300, *317
Seegmiller, J. E., *470
Seftel, Harold C., *303
Segall, M. M., *777
Segre, G., 570-578
Seidensticker, John F., *174
Seip, M., *718
Seltzer, Holbrooke S., *56-57
Serio, M., 124-126
Service, Frederick J., *342
Sethi, S., *342-343
Settle, Harold P., Jr., *592
Setyaadmadja, Albertus, *50
Seyffert, Willis A., Jr., *715
Shackleton, C. H. L., *407
Shaffer, Rose, 281-285
Shafrir, Eleazar, *411
Shames, Jay M., *471
Shapcott, Dennis J., *592
Shapiro, Stanley, 152-160
Shaw, Walter N., *310, 737-745
Sheehan, Suzanne K., *468
Sherman, Lawrence, *525, 557-559, *777
Shiao-Wei Shen, *323-324
Shrader, Ruth E., *589, *718
Shuman, Charles R., *302
Siegel, Charles I., *334
Siegel, Maureen, *334
Silvers, Abraham, *323-324
Simar, Leon J., 582-587
Simkins, Samuel, 136-140
Simmons, Earl M., *113
Simon, William T., *717
Simons, E. L., 673-678
Simpson, Ronald G., 684-692
Sisk, Charles W., *471
Sitbon, Guy, *57
Skillman, Thomas G., 48, *343
Slone, S., *336
Smith, Desmond F., *53
Smith, Harriet W., *350
Smith, J. Bruce, *469
Smith, J. S., *777-778
Smith, Mary Emma, *334
Snapir, N., *114
Snarr, J. F., *778
Sodero, A., *655
Sodero, Edgardo C., *337
Sodoyez, Jean C., *343, 582-587
Sodoyez-Goffaux, F., *343
Soeldner, J. Stuart, 17-26, *174, *298, *339, *344, 362-368, *406, 752-759
Soergel, Konrad H., *653
Sokal, Joseph E., 256-260, *712
Solbach, H. G., *775
Solomon, Harvey M., *175
Solomon, Solomon S., *116, *470
Sönken, P. H., *175
Sonnenblick, Edmund H., *776
Sotgia, Giulio, *57
Sotman, Stuart L., 427-436
Sparks, Lowell, L., *344
Spector, Samuel, *525
Spellacy, C. E., *344-345
Spellacy, William N., *344-345, *412, *592
Spergel, Gabriel, *57, *345, *592-593
Spiro, Mary Jane, *311
Spiro, Robert G., *311
Spitz, I., 161-169
Splitter, Stanford D., *323
Sprague, Randall G., 385-387
Spratt, Irving L., *345
Spriggs, T. L. B., 33-36

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

Stark, J. R., 13-16
Stauffer, Henry H., *318
Steele, Robert, 415-421
Steendijk, C., *116
Stein, Eduardo, *231
Steinberg, Daniel, *409
Steiner, Alton L., *778
Steiner, Donald F., *309-310, 725-736, 777
Steiner, George, *345-346
Steiner, H., *593
Steinke, Jurgen, *51, *406
Stephens, A. D., 402-405
Sterky, G., *56, *412
Stern, Michael P., *174
Stern, Sol, *346
Stewart, G. A., *712
Stimmler, L., *116, *406-407
Stock, Michael, *528
Stock, Richard, *527
Stocks, A. E., 175-176, *715-716
Stoddard, F. J., 37-47, *307
Stoll, Ralph W., *299
Stone, Daniel B., *50, *304, *340, *469
Storvick, Waldemar O., *311, 499-502
Straatsma, Bradley R., *649-650
Strauss, W. T., *409, *411, *773-774
Streeten, David H. P., *410-411
Strong, J. A., *713-714
Sturzenegger, V., *411
Subrahmanyam, K., *471
Su-Chen Li, *778
Sukkar, M. Y., *175
Sullivan, Benjamin H., Jr., *717
Sundby, F., *229
Sussman, Karl E., *320, *327
Sutherland, James M., *292-*293
Sweet, Elizabeth M., *776
Swendseid, Marian E., *57
Swiatek, Kenneth R., *593
Swislocki, Norbert L., *528
Szabo, Andrew J., *346-347
Szabo, Olga, 1-7, *333, *347
Szczepanik, Zdistawa, 492-498

T

Takano, Toshio, *116
Täljedal, Inge-Bert, *53, *292
Tamir, I., *777
Tanioka, Tatsuo, *173
Tarquini, B., 124-126
Taskinen, Marja-Riitta, 76-82, 209-218
Taubin, Howard, 108-109
Tawecki, January, 492-498
Taylor, Andrew L., *527
Taylor, K. W., *778
Teusen, R., *710
Thiffault, Charles A., *171, *524-525
Thorell, J., *56
Thorn, George W., *406
Thurston, Jean H., *309
Tieffenberg, M., *209, *412
Timme, A. H., *56
Tjabbes, T., *175
Tobias, C. A., *318
Toccafondi, R., 124-126
Tometsko, Andrew M., *54, *292, *410
Tosteson, Daniel C., *290, *412
Touber, Jan L., *313, *347
Track, N. S., *774, *778-779
Trakatellis, Anthony C., *292, *410
Tramuta, Anthony, *525
Tranquada, Robert E., *170-171
Treble, Donald H., *778
Treser, Gerhard, *301
Trey, C., *56
Trygstad, O., *718
Tsukamoto, Masaru, *234
Tuna, N., *471
Tung, A. K., *294
Turner, D., *779
Turner, L. J., *715
Turtle, John R., *528
Tuttle, Stewart G., *57
Tyson, J. E., *347
Tzagournis, Manuel, *58, *343, *347-348, *653

U

Ungar, Berta, *175-176
Unger, Roger H., *312, *321-322, *715
Ureta, T., *113

V

Valdellon, Moding, *340
Vallance-Owen, J., *58, *116
v. Baeyer, H., *56
Vance, James E., 179-186, 187-193, *299, *311-312, *321-322
Van Der Hagen, C. B., *718
Van Harken, Donald R., *176
Varandani, P. T., 547-556
Vargas-Cordon, Mario, 617-624
Vaughan, Gary D., *320
Veverbrants, Egils, *348
Viktora, Josef K., *175, *176, *350, *715
Vinik, A. I., *328-329, *348, *590, *779
Vinnick, Leonard, *312, *469
Vitelli, A., 570-578
Volk, Bruno W., 152-160, *176, *306-307, *330-331
Voyles, Nancy, *330, 374-384, 746-751
Vranic, M., *348-349

W

Wales, John K., *176, *528, *715
Walfish, Paul G., *349
Walker, F., 105-107
Wallace, D., *412
Walters, Eileen, *526-527
Waterhouse, Christine, *654
Watkins, P. J., 398-401
Wegienka, Laurence C., *50, *176, *589
Weil, William B., Jr., *718
Weinberg, Myron S., *346
Weiner, Murray, *779
Weinhouse, Sidney, *231, *408
Weinsten, Jacob J., *318-319
Weir, Gordon C., *305
Weis, L. S., *304
Weisenfeld, Shirley, 766-771
Weissman, Burton, *302
Wellmann, Klaus F., *176, *306-307
Wells, Lemen J., *651
Wells, Sally A., *307-308
Westerman, M. P., *468
Westman, Sighild, *593
Whaley, William H., *176
Wheelcock, Frank C., *326
Whichelow, M. J., *412, *651, *779
White, Priscilla, *339, 708
Whitehouse, F. W., *319, 520-521
Whittingham, Senga, *175-176
Whittington, T. H., *656
Widdas, W. F., *651, *773
Wilder, Russell M., Jr., *349-350
Williams, Christine, *294
Williams, R. F., 17-26, *350
Williams, Robert H., 53-54, *116, 179-186, 187-193, *297, *322-323, *330, *716
Williamson, H. O., *409-410
Williamson, John R., 194-208
Willoughby, J. M. T., *713-714
Wilson, Dana E., *306
Wilson, J. S. P., *58, *116
Wilson, Strathearn, *231
Winegrad, Albert I., *299-300
Winick, Myron, *234
Wisniewskui, Konstanty, *471
Wolf, S., *114
Womack, William, *291, *326, *336-337
Wong, Kai K., *349
Wood, Francis C., *299
Wool, Ira G., *58
Woosley, R. L., *469
Wright, A. D., *655
Wright, Peter H., *55, *58, *308-309, 513-516, 537-546, 641-645, *718
Wu, C. H., *338, *655
Wulff, J., *114
Wynn, V., *653
Wolff, Frederick W., *176, *338, *350, *528, *715

Y

Yakimets, Walter W., *340
Yamagata, Shoichs, *470
Yeboah, J.-E., *294
Yeung, Rose, 219-228
Yip, C. C., *294
Yodaiken, Ralph E., *303, *316
Young, D. A. B., *58
Yu, Ts'ai-Fan, *593
Yu-Teh, Li *778

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788

Z

Zacharewicz, Francis A., *350
Zaharko, Daniel S., 444-457
Zahn, Helmut, *656, *718
Zalut, Clyde, *54, *292, *410
Zarebski, Maciej, *471
Zeballos, Gillermo, *112
Zeigler, Marcia, 8-12
Ziegler, W. H., *233
Zelmanovsky, Sophia, 579-581
Zierler, Kenneth L., *589
Ziff, Lawrence, 766-771
Zitomer, Barry R., *412
Zizi, P., 489-491
Zorrilla, Alfredo Hernandez Eduardo, *327, *339
Zubas, Dana, *348
Zubowski, Andrzej, *230
Zucker, Stanley, *172
Zuspan, Frederick P., *176
Zwi, S., *777

DIABETES: VOLUME 17 (1968) PAGE NUMBERS BY ISSUE

January, 1-60
February, 61-120
March, 121-178
April, 179-238
May, 239-296
Annual Meeting Supplement, 297-352
June, 353-414
July, 415-474
August, 475-536
September, 537-598
October, 599-660
November, 661-724
December, 725-788